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Genome editing mediated by engineered nucleases, including Transcription 
Activator-Like Effector Nucleases (TALENs) and Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) / CRISPR-associated (Cas) systems, holds great potential 
in a broad range of applications, including biomedical studies and disease treatment. In 
addition to creating cell lines and disease models, this technology allows generation of 
well-defined, genetically modified cells and organisms with novel characteristics that can 
be used to cure diseases, study gene functions, and facilitate drug development. However, 
achieving both high efficiency and high specificity remains a major challenge in 
nuclease-based genome editing. The objectives of this thesis were to optimize the design 
of TALENs to achieve high on-target cleavage activity, and analyze the off-target effect 
of CRISPR/Cas to help achieve high specificity. Based on experimental evaluation of 
>200 TALENs, we compared three different TALEN architectures, proposed new 
TALEN design rules, and developed a Scoring Algorithm for Predicting TALEN Activity 
(SAPTA) to identify optimal target sites with high activity. We also performed a 
systematic study to demonstrate the off-target cleavage by CRISPR/Cas9 when DNA 
sequences contain insertions or deletions compared to the RNA guide strand. Our results 
strongly indicate the need to perform comprehensive off-target analysis, and suggest 
specific guidelines for reducing potential off-target cleavage of CRISPR/Cas9 systems. 
The studies performed in this thesis work provide important insight and powerful tools 
for the optimization of engineered nucleases in genome editing, thus making a significant 
contribution to biomedical engineering and medical applications.  
 
1 
CHAPTER 1: INTRODUCTION 
1.1  Genome editing approach to treat diseases 
  Single gene disorders account for over 10,000 diseases(8), including a large 
number of prevalent diseases, such as sickle-cell disease (SCD), cystic fibrosis (CF), and 
spinal muscular atrophy (SMA). These gene disorders impose a significant health and 
financial burden worldwide. Sickle cell disease (SCD) is a well-studied paradigm of 
single gene disorders. The majority of SCD patients carry an A to T mutation in both 
alleles of the β-globin gene (HBB) that changes a single amino acid from glutamate to 
valine. This small change leads to a malfunctioned form of adult hemoglobin, shortening 
the lifespan and rendering painful symptoms and complications for patients(9). Although 
blood and marrow stem cell transplants may cure a small number of patients, there is no 
widely available cure for this disease.  
 Genome editing techniques hold great potential in treating challenging diseases by 
precise manipulation of the genome, especially with the application of sequence-specific 
designer nucleases (Figure 1). With wild-type donor templates, the DNA double stranded 
break (DSB) generated by the designer nucleases can be repaired through the 
homologous recombination (HR) repair pathway, which will use the genetic information 
provided by the donor template to correct the SCD mutation.  
 In the absence of a donor DNA, the DSB will be repaired by the non-homologous 
end-joining (NHEJ) pathway. This error-prone pathway can then generate insertions and 
deletions at the site of the DSB to inactivate a gene, or a large targeted deletion in the 
range of kilobases if two DSBs are created at adjacent sites on a chromosome(10,11). The 
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NHEJ-mediated genome editing can be applied to inactivate essential genes of HIV 









 Gene targeting approach can potentially cure SCD at molecular levels by 
introducing the corrected DNA sequence to replace the sickle cell mutation using HR 
pathway. However, the application of this approach has been limited by its low 
 
Figure 1: Nuclease-mediated genome editing.  
A DNA double stranded break (DSB) generated by engineered nucleases, such as ZFNs, TALENs, or 
CRISPRs, can be repaired by one of the two major DNA repair pathways: homology-directed repair 
(HDR) or non-homologous end-joining (NHEJ). These repair mechanisms will lead to different 
modifications in the genome.  
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efficiency. It was found that the efficiency of gene targeting can be substantially 
improved by the use of designer nucleases to generate DSBs in target genes, which then 
stimulate the HR pathway(12). By correcting the “sickle” mutation in hematopoietic stem 
cells from patients ex vivo and infusing the corrected cells back into patients, we may be 

















Donor  DNA with 
correct sequence
HR
Corrected CD34+ cells  
Figure 2: Schematic of genome editing approach to treat SCD.  
Blood cells from patients can be enriched for hematopoietic stem cells by sorting for the CD34 
marker on cell surface. Enriched cells are treated with engineered nucleases and donor DNA with 
correct, non-sickle sequence. Cells containing corrected stem cells can be infused back into patients to 
generate healthy red blood cells. 
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 Designer nuclease can also be simultaneously targeted to two adjacent sites on the 
same chromosome to obtain targeted deletion of large DNA fragments. Our lab proposed 
to treat HIV-infected cells by excising the integrated HIV proviruses from the genome. 
Although progress has been made in prevention and treatment of HIV, the HIV-infected 
population continues to grow and remains a major concern of global health. The number 
of people living with HIV in 2008 was estimated to be 33.4 million(13). Highly active 
antiretroviral therapy (HAART) has been remarkably successful, often resulting in 
undetectable level of viral load in treated patients. However, complete eradication of HIV 
infection has thus far been unattainable, due to the protected reservoirs of latently 
infected cells (14). We proposed to design engineered nucleases to cleave the common 
sequences shared by 5’ and 3’ long terminal repeats (LTRs) located at both ends of the 
HIV genome, thus excising the integrated HIV provirus after two concurrent DSBs are 
generated in the chromosome (Figure 3). This unique strategy could truly remove virus 









1.2  Engineered nucleases used in genome editing 
 The approaches described above that use genome editing approach to treat SCD 
and HIV infection require well-designed engineered nucleases which are highly 
sequence-specific and highly active. Several major classes of designer nucleases— 
meganucleases, Zinc Finger Nucleases (ZFNs), TALENs, and CRISPRs—have been 
successfully deployed in gene engineering(12,15-18) in different organisms for 
applications ranging from creating model organisms to treating genetic diseases. A 
barrier to the widespread application for meganucleases and ZFNs has been difficulty in 
obtaining new DNA sequence specificities through rationale design. This is largely due to 
the context dependent nature of their DNA-binding units. TALENs and CRISPRs have 
been developed rapidly into major tools for genome manipulation as it is much easier to 
 
Figure 3: Schematic of removing the HIV provirus from infected human cells.  
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design than other designer nucleases due to their predictable and context-independent 








 TALENs are a family of DNA binding proteins, discovered in the plant pathogen 
Xanthomonas(19-22). Each DNA-binding domain contains a variable number of 33-35 
amino-acid repeats that specify the DNA-binding sequence primarily through their 12th 
and 13th repeat-variable di-residues (RVDs)(19). Each RVD specifies one nucleotide 
with minimal context dependence(20,22,23). A TALEN targets a specific DNA sequence 
Figure 4: The architecture of TALEN.  
(a) Structure of TALEN. The repeat domain which directly recognizes DNA molecules is flanked by 
an N-terminal domain with 136 amino acids and a C-terminal with 63 amino acids. The amino acid 
sequence of one repeat is shown with RVD boxed in yellow. The RVDs recognizing each nucleotide 
are shown on the right. The 3X FLAG epitope and nuclease localization signal (NLS) are also shown.  
(b) Schematic of a pair of TALENs generating a DSB in the target site. 
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by designing a set of repeats flanked by modified N- and C-termini(24,25) and linked to a 
FokI nuclease domain(15,26,27). When a pair of TALENs binds to their specific half-
sites with the correct orientation and spacing to allow the nuclease domains to dimerize, 
the intervening sequence is cleaved (Figure 4). TALENs have been used to edit genomic 
DNA sequences in a variety of biological systems, including human cells, rats, zebrafish, 









Figure 5: The architecture of the CRISPR/Cas9 system.  
The guide RNA is a chimeric RNA with the first 20-nt sequence complimentary to the genomic DNA 
sequence at the target site. This 20-nt guide sequence direct where the Cas9 nuclease cleaves. The 
protospacer-adjacent motif (PAM) is a short sequence required right next to the target site 
(protospacer) for the CRISPR/Cas9 system to function.   
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 CRISPR and CRISPR-associated (Cas) proteins constitute a bacterial defense 
system that cleaves invading foreign nucleic acids (33-40). Chimeric single-guided RNAs 
(sgRNAs) based on CRISPR (41) have been engineered to direct the Cas9 nuclease to 
cleave complementary genomic sequences when followed by a 5’-NGG protospacer-
adjacent motif (PAM) in eukaryotic cells (17,42,43). Since gene targeting by 
CRISPR/Cas9 is directed by base pairing, such that only the short 20-nt sequence of the 
sgRNA needs to be changed for different target sites, CRISPR/Cas systems enable 
simultaneous targeting of multiple DNA sequences and robust gene modification 
(17,18,41,42,44-48). 
1.3  Project overview 
One challenge in TALEN design has been choosing an optimal RVD to recognize 
guanine. As shown in Figure 4, NN (Asn-Asn), NK (Asn-Lys), and NH (Asn-His) are 
three guanine-specific RVDs that can be used to construct TALENs for a specific DNA 
target sequence. NN RVD has been the most commonly used RVD for guanine. TALENs 
with NN RVDs (NN-TALENs) have a higher binding affinity than those with NK RVDs 
(NK-TALENs); however, their specificity is low since NN RVDs bind to both guanine 
and adenine (1,24,30,49,50). Recent studies investigated a new RVD NH using TAL 
effectors, which activate transcription once bound to a specific sequence. The results 
show that the NH RVD gives medium to high activity, together with a high 
specificity(1,50). While the NH RVD appears to be promising, it still remains to be seen 
whether high activity and specificity can be obtained when this RVD is built into 
TALENs. Specific Aim 1 addressed the question on which RVD to choose for optimized 
TALEN performance. 
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 Another challenge in TALEN design is obtaining high nuclease activity while 
using the RVD NK that favors specificity rather than activity. The codes of nucleotide 
recognition by RVDs have been established(20,22), as shown in Figure 4a. If we choose 
NK as the G-specific RVD, for a given DNA sequence, we can readily assemble an array 
of repeats with corresponding RVDs to recognize the sequence. The design of TALEN is 
thus equivalent to choosing an optimal target DNA sequence. Due to the weaker RVD 
efficiency of NK, it has been difficult to obtain active NK-TALENs without careful 
selection of target sequences. Specific Aim 2 of this thesis addressed the question 
regarding selection of TALEN target sites for achieving high nuclease activity.  
 The major concern in targeting genes with CRISPR/Cas9 systems is their 
relatively low specificity. Recent studies reveal that CRISPR can even cut at genomic 
sites containing up to five base mismatches out of the total 20-nt target sequence(5,51-
55). Carefully selection of target sites less similar to other genomic sequences becomes 
critical in designing CRISPRs. However, it is not definitive that mismatch is the only 
type of sequence variance that can be tolerated by CRISPRs, so other sequence variances 
also need to be interrogated to ensure specific genome editing by CRISPR/Cas9. Specific 
Aim 3 focused on the identification of CRISPR off-target effect at genomic sites 
containing missing bases (deletions) or extra bases (insertions) compared to the guide 
RNAs. 
 The goal of the thesis is to improve the performance of two new classes of 
engineered nucleases, TALENs and CRISPRs. The results will provide the community 
with a powerful and reliable tool for genetic engineering to treat and model diseases. 
Optimized engineered nucleases will also enable the development of novel paradigms in 
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curing single gene disorders and HIV infection using genome editing approaches. The 
goal of this thesis is fulfilled by performing studies with the following specific aims: 
Specific aim 1 
 This aim is to optimize TALEN architecture by comparing the activity and 
specificity of TALENs constructed with different repeat-variable di-residues (RVDs) 
recognizing guanine. TALENs targeting sites in the different human genes were 
constructed with one of the three different RVDs, Asn-Asn (NN), Asn-Lys (NK), and 
Asn-His (NH). The on-target and off-target mutagenesis of TALEN pairs containing 
different RVDs was measured by a T7 endonuclease I (T7E1) mutation detection assay 
and deep sequencing with PCR products amplifying the genomic sites in HEK293T cells. 
The ability of these TALENs to trigger homology-directed repair (HDR) at the β-globin 
gene is quantified by the percentages of stably integrated GFP gene in K562 cells.  
Specific aim 2 
 This aim is to develop a scoring algorithm to predict TALEN activities and 
validate its ability to predict optimal TALEN target sites. Around two hundred TALENs 
were designed to target sequences with different features, and constructed using a high-
throughput protocol involving robot liquid handler. TALEN monomer activity was 
measured by the modified single-strand annealing (SSA) assay in HEK293T cells. A 
Scoring Algorithm for Predicting TALEN Activity (SAPTA), which gives a numerical 
score that predicts TALEN activity (a high score predicts a high activity), was developed 
using the measured monomer activities as training-set data. We then designed TALEN 
pairs targeting disease-related genes using SAPTA and measured the monomer and pair 
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activities in HEK293T cells. The results were used as test-set data to validate the 
effectiveness of the algorithm. 
Specific aim 3 
 This aim is to discover and characterize another dimension of CRISPR off-target 
effect in addition to mismatch tolerance. Guide RNAs target to HBB and CCR5 genes 
were modified by deleting bases from or inserting bases into the guide sequences, and the 
mutagenesis at these genes resulted from the guide RNA variants was quantified using 
the T7E1 assay in HEK293T cells. We then scanned the human genome for potential off-
target sites containing insertions or deletions compared to randomly designed guide 
RNAs targeted to different genes. T7E1 assay and deep sequencing were used to detect 
any mutations at these potential off-target sites. An online tool that searches for genomic 
sites containing mismatches, insertions, and deletions was developed to help researchers 




CHAPTER 2: NUCLEASE ASSEMBLY AND TEST PIPELINE 
2.1  Construction of TALENs 
 The ability to assemble TALENs in a high-throughput manner is essential for 
carrying out studies in this proposal. Construction of TALENs is not straight-forward due 
to the repetitive DNA sequence coding the TALEN DNA-binding domains. Various 
methods based on the Golden Gate (GG) cloning reaction were developed to overcome 
the difficulty(2,23,56,57).   
 We have successfully assembled TALENs using a hierarchical ligation-based 
strategy which involves two steps with one Golden Gate (GG) cloning reaction in each 
step(23). Plasmid tool kit was kindly provided by Dr. Daniel F. Voytas, University of 
Minnesota. These plasmids contain individual TALEN DNA-binding repeats, 
intermediate backbone vectors, and final destination backbone vectors. Repeat-encoding 
plasmids contain RVDs HD, NI, NG, and NN to recognize nucleotides C A, T, and G, 
respectively. There are two additional sets of repeat plasmids with RVDs NK and NH to 
recognize guanine.  
 The first GG reaction using BsaI restriction sites links individual DNA-binding 
repeats into an intermediate array of 10 or less repeats. Plasmids containing intermediate 
arrays are sequence confirmed. In the second GG reaction, these intermediate arrays and 
final repeats are further ligated together into a pcDNA3.1(-)-based backbone vector (3) 
using BsmBI restriction sites to replace a lacZ gene stuffer fragment for blue/white 
screening. The backbone vector was constructed by incorporating a Kozak sequence, a 
triple FLAG epitope tag, and a previously described TALEN framework (24) into the 
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pcDNA3.1(-) vector using NheI and AflII restriction sites (backbone vector kindly 
provided by Dr. Matthew H Porteus, Stanford University).  
 A detailed protocol of Golden Gate TALEN assembly published by Voytas Lab 
can be found on www.addgene.org. This assembly method was programmed by us into a 
protocol which can be processed by a Beckman Coulter Biomek 3000 liquid-handling 
robot. This allows high-throughput, error-free assembly of TALENs. After optimizing the 
protocol, >90% of colonies generated from each GG reaction are positive and contain the 
correct sequences. Typically a batch of TALEN-encoding plasmids can be constructed 
within two weeks, including the time for sequencing intermediate arrays and final 
constructs. Complete sequences of all TALEN plasmids can be generated using the TAL 
plasmid assembly website (bit.ly/assembleTALsequences). 
2.2  Measurement of nuclease-mediated DNA modification 
Measurement of NHEJ-mediated gene mutation 
 T7E1 assay was used to quantify mutation resulted from nuclease cleavage and 
subsequent NHEJ repair in the genome. This assay determines the percentage of mutated 
alleles in the population of cells treated with nucleases, which is an indication of the 
gene-modifying activity of the nuclease tested (Figure 6). This enzyme-based assay can 
be done in less than one day without expensive equipment, and do not require co-deliver 
of constructs other than nucleases into cells, so is widely used to estimate the activity of 
nucleases at endogenous genes in mammalian cells. 
 HEK293T cells were transfected with plasmids encoding both TALENs that form 
a pair, and pEGFP plasmid. Cells will be harvested 72 h after transfection and analyzed 
with an Accuri C6 flow cytometer to quantify GFP fluorescence, as a measurement of 
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transfection efficiency. Cell pellets were then collected and genomic DNAs were 
extracted. Transfected TALENs generated DSBs at the target sites or off-target sites in 
the genome. The DSBs were repaired mainly through the error-prone NHEJ pathway, 
generating insertions and deletions at the cleaved site. To perform the T7E1 assay, 
predicted TALEN cleavage sites were PCR-amplified from the genomic DNAs. DNA 
strands in the PCR product were denatured at a high temperature (95 °C) and allowed to 
cool down slowly, during which process DNA strands were randomly annealed. Re-
annealed products contain mismatch “bubbles” due to the presence of mutations (Figure 
6). T7E1 enzyme was then added to the re-annealed products, and cleaved at the 
mismatch “bubbles”. The cleaved bands were visualized on 2% agarose gels, and used to 
quantify the percentage of insertions and deletions (% indels) following instructions(58). 
The gel images were analyzed using ImageJ, and the following equation: % indels = 100x 
(1 – (1-fraction cleaved)^0.5), assuming the mutations resulted from NHEJ will all be 
different from each other. 
 The negative control cells were transfected with a nonrelated filler plasmid 
(pUC19) and pEGFP plasmid. To ensure that the cleavage bands are due to NHEJ 
followed by TALEN-induced DSBs, and not due to polymorphism, we amplified each 
target locus in the genome using genomic DNA from negative control cells as template. 
Negative PCR products were also subjected to the T7E1 assay, and compared with the 
treated samples as shown in Figure 6. 
 T7E1 assay has been used routinely to measure endogenous gene-targeting 
efficiency of engineered nucleases(2,31). This assay can sometimes under-estimate 
mutation levels if a substantial portion of mutations have the same sequence (less chances 
 15
of forming hetero-duplexes with strands sharing the same mutation). Due to the limited 
sensitivity of DNA stain on gels, T7E1 assay has a detection limit of ~1%. To detect a 









Measurement of HDR-mediated gene editing  
 HDR allows site-specific, user-designed gene editing / addition if providing cells 
with targeting DNA constructs (donor) containing a user-defined gene fragment (e.g. 
 
Figure 6: Schematic for T7E1 mutation detection assay.  
(a) TALENs cleave genomic DNA and result in mutations mediated by NHEJ. (b) T7E1 assay 
measuring the percentages of mutated alleles in treated cells. T7E1, T7 endonuclease I enzyme. % 
indels, percentages of insertions and deletions. --, negative control sample treated without TALENs. 
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transgene or edited sequence) flanked by substantial amount of homologous sequences to 
the target locus. Spontaneous DSBs randomly occurring at the target locus can lead to 
HDR using the homologous donor DNA provided. After repair, the chromosome will 
contain a copy of the genetic information we include between the two regions of 
homology. However, the frequency of gene editing for the spontaneous HDR is typically 
from 10-5 to 10-6 before selection (59). Generating a DSB at the target locus can 
dramatically increase the frequency of HDR (60). Site-specific engineered nucleases, 
ZFNs, TALENs, and CRISPRs, have successfully accelerated targeted gene engineering 
(Figure 7). Following the nuclease cleavage at the target site, the frequency of HDR can 
reach the range of 10-1 without selective pressure. To determine the frequency of 









Figure 7: HDR-mediated targeted gene editing using a donor template with homology.  
Edited sequence (Edited seq) can be a new transgene to be integrated into genome, or specific 
nucleotide changes at an endogenous gene, such as correcting the “sickle” cell mutation. 
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Measurement of HDR using GFP signal 
 To test the ability of nucleases to stimulate HDR, we can include a GFP gene with 
a constitutive promoter between the two homology arms shown in Figure 7. Upon 
successful homologous recombination, this GFP cassette will be integrated into the 
genomic locus, and be stably maintained through cell passages. If not integrated into the 
genome, the GFP-containing donor plasmid will be diluted over time, resulting in a 
decrease of GFP signal. After continuous culture of transfected cells for several weeks, 
non-integrated GFP signal will be lost, the levels of stable GFP signal following the 
signal decrease thus indicate the successful gene targeting through HDR (Figure 8). 
When TALENs are co-transfected with donor plasmids, the percentages of stably 
integrated GFP will be substantially increased compared to cells transfected with donor 











 This method is easy to perform and can detect a small percentage of gene 
targeting down to 0.1% if sorting through a large number of cells using flowcytometry. 
However, this method is time-consuming and often takes several weeks to perform. 
Moreover, if the nucleases have substantial activity at off-target sites, the GFP cassette 
can be stably integrated at the off-target sites, resulting in an overestimation of gene 









Figure 9: RFLP assay by introducing silent mutation(s) to form a new restriction site.  
(a) Gene editing using HDR introduce specific mutations of nucleotides, resulting in a new restriction 
site at the genomic locus. (b) example of RFLP assay visualized by an agarose gel. 
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Measurement of HDR using restriction fragment length polymorphism (RFLP) assay 
 To measure the frequency of HDR repair occurred at a genomic locus without 
introducing a reporter gene, we can use the restriction fragment length polymorphism 
(RFLP) assay. By introducing a few silent mutations in the donor template that do not 
alter the amino-acid sequence of a protein-coding gene, the repaired sequence can be 
differentiated from wild-type or randomly mutated sequences. The silent mutations can 
often be designed so that the resulting sequence contains a new restriction site. After 
nuclease-mediated gene editing, the genomic locus edited to contain this restriction site 
can be PCR amplified. PCR products can then be digested by this restriction enzyme, so 
the amount of cleaved bands indicates the percentages of alleles successfully edited 
(Figure 9). 
 RFLP assay can be performed at day three to day five after transfection, so the 
results of HDR can be visualized quickly and conveniently using a restriction digest. 
However, due to the sensitivity of DNA stain on an agarose gel, this assay has a detection 
limit of ~1%. The frequency of successful gene targeting through homologous 
recombination in human cells rarely reaches 10%, especially in stem cells, where often 
<1% of HDR is observed (unpublished data). In this case, a deep sequencing method is 
needed instead of RFLP assay.    
Sequencing analysis of gene modification  
 Regular Sanger sequencing and high-throughput next-generation sequencing 
(NGS) can also be used to visualize and quantify the genomic changes. Compared to the 
assays above where enzymes and flowcytometer are used, sequencing methods allow 
visualization of the actual sequence changes introduced by gene engineering. For 
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example, an “indel spectrum” can be seen by sequencing, which shows the occurrence of 
sequencing reads with different numbers of inserted bases or deleted bases (61). 
Furthermore, deep sequencing methods using platforms developed by Illumina and 
Pacific Biosciences are able to detect rare gene modification events around 0.1%. Below 
we describe two methods of sequence analysis for gene modification.  
TOPO-cloning and Sanger sequencing 
 After PCR amplification of genomic regions containing predicted nuclease cut 
site, PCR products can be ligated into plasmid vectors using commercially available kits, 
such as the TOPO TA Cloning Kit (Life Technologies). The ligated library is transformed 
into competent cells, and plasmids from individual colonies are extracted and sequenced 
by regular Sanger method. Normally 20 to 100 clones can be sequenced for a genomic 
locus, giving a sensitivity of 5% to 1%. Sequences of individual colonies are aligned to 
the wild-type sequence. Any sequence containing inserted or deleted bases is called an 
“indel” (insertion or deletion) read, and the number of indel reads divided by the total 
number of sequences (reads) is named “% indels” (Figure 10). The “% indels” is widely 
used as an indication of nuclease activity.  Purification of plasmids and sequencing a 
large number of plasmids can be time-consuming and costly. If a large number of cut 
sites need to be analyzed, high-throughput next-generation sequencing is preferred. 
Next-generation sequencing / deep sequencing 
 If higher sensitivity is desired, next-generation sequencing (NGS) may be used to 
generate millions of reads per run. Using spatial separation methods, NGS methods can 
simultaneous sequence millions of reads in a single run, allowing cost-effective high-
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throughput DNA sequencing. DNAs from hundreds of samples can be pooled together 








Figure 10: Sequencing results of the target loci aligned with ten most abundant mutated sequences.  
The target gene name, TALEN index and percentage of modified alleles (% indels) are indicated 
above each set of results. TALEN target sites are highlighted in yellow on the endogenous gene 
sequence, marked as wild type “WT”.  Deletions are shown as red dashes with a grey background. 
Insertions are highlighted in blue.  The numbers to the right of each sequence read indicate the bases 
inserted (+) or deleted (Δ) and further right, the number of times each sequence was found. 
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 Samples containing different sequences can be differentiated easily by aligning to 
their references respectively. If several samples share the same sequence (e.g. PCR from 
the same genomic locus), 8-bp barcode sequences were used to label these samples. 
Following sequencing, millions of reads were grouped into different barcodes, and were 
aligned to their reference sequences separately for each barcode. Within a group of reads 
corresponding to one specific sample identified by its barcode and sequence, we then 
counted the reads contain inserted bases or deleted bases compared to the reference 
sequence, and calculated the “% indels” as describe in the section above.   
 When we pool 200 genomic loci into a run, each locus is able to achieve around 
10,000 reads, so theoretically a sensitivity of 0.01% mutation can be detected. However, 
background noise associated with the sample preparation steps and the sequencing run 
may obscure very small percentages of mutation. To characterize background noise, we 
included a negative control PCR amplifying a mock-treated cell sample with every PCR 
we performed. By comparing the sequencing results from the nuclease-treated samples 
and mock-treated samples, genetic changes associated with nucleases can be 
differentiated from background sequence changes possibly due to DNA polymorphism, 
PCR error, or sequencing error.  
 Background noise can be reduced by specifying a narrower window when 
counting insertions and deletions. It is often suitable to assume that only insertions and 
deletions located around the predicted nuclease cut site are caused by nuclease cleavage. 
In a sequence read of several hundred bases, we could ignore the indels outside a window 
of 10 bp before and after the cut site. This ±10 bp window allows us to filter out the 
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majority of irrelevant sequence changes. This window can be enlarged or narrowed 
depending on the levels of noise and the property of nucleases.  
Measurement of nuclease-mediated DNA modification at a target plasmid 
 Nuclease cleavage at an endogenous gene can be affected by genomic context, 
including epigenetic factors, competing transcription factor binding sites and secondary 
structures. To bypass the effect of genomic context and focus on the intrinsic activity of 
nucleases, we also measure nuclease activity in HEK293T cells using a modified single-
strand annealing (SSA) assay, which test the results of nuclease cutting at a target 
plasmid containing nuclease target sites. Nuclease-encoding plasmids and the 
corresponding target plasmids were co-transfected into HEK293T cells, and the 
percentages of plasmids repaired by the SSA pathway were quantified. 
 SSA assay measures the repaired plasmids following nuclease cleavage at the 
plasmid and SSA repair mechanism. SSA pathway is a type of homologous 
recombination that repairs a DSB between two adjacent repeat sequences in the same 
strand (Figure 11)(62). When the DSB is repaired by the SSA pathway, the sequence 












                 AscI                                         EcoRI 
TCTTCAAGGACGACGGCGCGCCTAGCAACCTCAAACAGACACCATGGTGCACCTATCGATGAATTCTTAAGAGG






Expected sequence of SSA-repaired segment 
GCCCGAAGGCTACGTCCAGGAGCGCACAATTTTTTTCAAGGATGATGGAAACTACAAGACCCGCGCCGAGGTGA
 
TOPO-cloned SSA-repaired sequences 
 
Figure 11: Modified SSA assay to test nuclease activity cutting a target plasmid.  
(a) Schematic of the modified SSA assay. (b) Samples from a representative SSA assay used to 
quantitate the PCR products amplified from HEK293T cells. (c) An example of a homo-dimeric target 
plasmid segment. The target site in the sense strand and reverse complement of the antisense target site 
are highlighted in yellow. The GFP-ZFN target site is shaded in grey. The 42-bp repeats flanking the 
target site are shaded in black. The EcoRI site in the spacer and AscI and SbfI restriction sites are 
underlined. (d) Sequencing chromatograms of four TOPO-clones from gel-isolated SSA-repaired 





 We made SSA target plasmids by cloning nuclease target sequences between two 
repeats to facilitate SSA assay (3). An SSA backbone plasmid should contain two repeat 
sequences separated by one or more stop codons, an optional control target site, and two 
unique restriction sites that are each present once plasmid. Our SSA backbone plasmid 
contains an EGFP gene, interrupted after 327 bp with a stop codon, the target site for a 
pair of GFP-targeted ZFNs(63), an AscI, and an SbfI cloning sites (plasmid kindly 
provided by Dr. Matthew Porteus, Stanford University). The downstream portion of the 
EGFP gene includes a 42-bp region repeating the sequence of the EGFP gene before the 
stop codon (Figure 11). The ZFN target site can be used as an activity control when the 
SSA plasmid is co-transfected with the GFP-ZFNs.  
 The two restriction sites, AscI and SbfI, are used to insert TALEN target sites that 
includes a left binding site, followed by a spacer and a right binding site (Figure 12). 
Three pairs of oligonucleotides that contain the left TALEN half-site, a spacer with an 
EcoRI site, and the right TALEN half-site are ligated into the vector. The ends of each 
oligonucleotide pair are compatible with its adjacent oligonucleotide pair(s) or the 
backbone vector. Various spacers from 11 bp to 30 bp with arbitrary sequences can be 
used in the ligation. Oligonucleotide pairs containing TALEN half-sites (red lines with 
arrows) can be used in assembling both homo-dimeric TALEN targets and hetero-dimeric 
TALEN targets. If the left binding sequence on the sense strand and the right binding 
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sequence on the anti-sense strand are the same, the target plasmids are “homo-dimeric”, 








 Plasmids encoding a TALEN monomer were co-transfected with the 
corresponding homo-dimeric target plasmid carrying the pair of TALEN binding half-
sites separated by a 17-bp spacer. If the plasmid is cleaved by TALEN homo-dimers and 
repaired by the SSA pathway, the fragment is smaller from the loss of the target sites and 
bases between the 42-bp repeat sequences. Following PCR amplification of a region 
flanking the target site using primers specified in (3), the PCR products were analyzed by 
agarose gels which separated the 345-bp PCR fragments amplified from SSA-repaired 
 
Figure 12: Assembly of TALEN target plasmid.  
(a) Schematic of target plasmid assembly. (b) Examples of oligonucleotide pairs for making the target 
plasmid are shown with each sense and anti-sense oligonucleotide paired. The overhangs of these 
oligonucleotide pairs were designed to be complementary for annealing and ligation of the three oligo 
pairs into the backbone vector. 
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reporter plasmids and the 514-bp PCR fragments amplified from uncut or NEHJ repaired 
plasmids (Figure 11b) (3). The percentage of the SSA-repaired products relative to the 
total PCR products was determined using ImageJ. The negative controls cells were 
transfected with an empty TALEN backbone and an SSA reporter plasmid.  The positive 
control cells were transfected with a pair of GFP-ZFNs(63) and an SSA reporter plasmid.  
Another control sample was transfected with pEGFP plasmid and an empty TALEN 
backbone to estimate the transfection efficiency by quantifying the percentages of EGFP-
positive cells. The 345-bp band, as shown in Figure 11b, was gel-isolated, cloned into 
pCR4-TOPO vector (Life Technologies) and sequenced using T3 primer. The sequencing 




CHAPTER 3: COMPARISON OF TALENS CONSTRUCTED WITH 
DIFFERENT GUANINE-TARGETING RVDS 
 The modular DNA binding of TALENs is enabled by the one-to-one interaction 
between repeat-variable di-residues (RVDs) and nucleotides. Specific recognition of 
guanine has been controversial because three RVDs, NN (Asn-Asn), NK (Asn-Lys) and 
NH (Asn-His), have been shown to target guanine with varied affinity and specificity, but 
the overall cleavage efficiency and genomic off-target effect of TALENs constructed 
with these three RVDs have yet to be well characterized. Here we constructed NK-, NH-, 
and NN-TALEN pairs for nine target sequences in the human genome. We quantified and 
compared the on- and off-target effect of TALENs with three different G-targeting RVDs 
at human genomic loci bearing one to 14 mismatches. NH- and NN-TALENs showed 
higher gene modification frequencies resulting from non-homologous end-joining 
(NHEJ) compared to NK-TALENs, whereas NN-TALENs stimulated highest frequencies 
of gene targeting by homologous recombination (HR). NK-TALENs were able to 
mitigate off-target cleavage at genomic sites harboring ≥3 mismatches, indicating an 
overall higher specificity compared to NH- and NN-TALENs. Our results will help 
researchers choose suitable G-targeting RVDs to construct TALENs where a balance 
between high on-target activity and minimal off-target activity is most critical, such as in 
clinical applications. 
3.1  Introduction 
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 The ease of TAL Effector Nucleases (TALENs) design has led to their effective 
use in genomic editing in a number of biological applications. The DNA-binding domain 
of TALENs contains a tandem array of 33-35 amino-acid repeats(15,26,27), with each 
repeat specifying one nucleotide through its 12th and 13th amino acids, the repeat-
variable di-residues (RVDs)(20,22).  TALENs are engineered to bind novel sequences by 
assembling the RVDs to correspond to the target sequence. There is a straightforward 
code linking RVDs in any context to their targeted nucleotide. RVDs NI (Asn-Ile), 
HD(His-Asp) and NG (Asn-Glu) specifically bind to nucleotides A, C, and T, 
respectfully(64). The exception is the nucleotides guanine (G), which has been targeted 
by engineered TAL effectors (TALEs) or TALENs using multiple RVDs, including NN 
(Asn-Asn), NK (Asn-Lys) and NH (Asn-His)(1,24,30,49,50). These RVDs bind with 
different affinity and specificity. The NN RVD binds to either G or A with relatively 
similar efficiency; the NK RVD has higher specificity but lower affinity in binding to G 
compared with NN. Studies of gene-regulating TALEs hinted that the NH RVD might 
combine these qualities and have high affinity and high specificity, though TALENs 
containing NH have not been characterized. 
 We have compared nine sets of TALENs that only differ in their G-targeting 
RVDs and have been constructed using NK, NH, or NN (KNH TALENs).  Each of these 
sets of KNH TALENs was transfected and tested in parallel for their ability to cleave 
their unique target sequence. To identify the RVDs that confer the best specificity, off-
target cleavage activities of KNH TALENs at genomic sites sharing similarities to the 
target loci were quantified by T7 endonuclease I (T7E1) mutation detection assay, Sanger 
sequencing, and Single Molecule Real Time (SMRT) sequencing. KNH TALENs were 
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further tested for their ability to stimulate gene targeting by homologous recombination. 
The activity and specificity results can be used to select the appropriate G-specifying 
RVDs to optimize cleavage activity and target specificity for ones genome engineering 
application. 
3.2  Results 
Comparing the activity of KNH TALENs at their intended targets 
 Each TALEN pair was constructed with one of the different G-targeting RVDs. 
These TALENs containing one of the most common three types of G-targeting RVDs 
(NK, NH, and NN) were tested in parallel to investigate in whether the change in activity 
resulted from switching G-targeting RVDs is universal (Figure 13). Besides the G-
targeting RVDs, we use NI to target A, HD for C, and NG for T. We thus built three 
versions of TALEN pairs targeting the same genomic sequence, but constructed with 
three different G-targeting RVDs, NK, NH, and NN, respectively. Nine sets of target sites 
were targeted by the KNH TALENs, respectively. The target sequences include loci from 
six genes: HBB, CXADR, CFTR, AAVS1, CCR5, and ATF4. Target loci in the HBB gene 
were selected around the sickle cell mutation, and other target sites were chosen using the 
SAPTA program (3) from the highest ranking sites within these genes. Four 
combinations of target sequences were tested for the HBB gene: S-02/S-05, S-02/S-12, S-
02/R-04, and S-116/S-120. These loci also contain various numbers of G in the left and 
right TALEN binding sites, ranging from zero to six, constituting 0% to 35% of the 









 TALENs containing the same G-targeting RVD were paired and transfected into 
HEK293T cells, and the gene mutagenesis resulted from non-homologous end-joining 
(NHEJ) DNA repair following TALEN cleavage was quantified using a T7 endonuclease 
I (T7E1) assay (Figure 15). The percentages of insertions and deletions (% indels) at the 
intended target sites indicate the efficiency of TALEN cleavage (Figure 16).  
 
 
Figure 13: Schematic of TALENs constructed with different G-targeting RVDs. 
(a) A set of three TALENs with the G-targeting RVDs switched to NK (blue), NH (red), and NN 
(green), respectively. The TALEN scaffold uses the +136/+63 architecture, with a triple FLAG tag (3X 
FLAG) and a nuclear localization signal (NLS)(3). Corresponding RVDs and their target nucleotides 
are listed on the right. (b) Three TALEN pairs with different G-targeting RVDs recognizing the same 
target site. Each pair of TALENs contains a single type of G-targeting RVD. NK-L, NH-L, and NN-L 
are left TALENs containing NK, NH, and NN, respectively. NK-R, NH-R, and NN-R are right 






 We found that at their intended target sites, NH- and NN-TALENs show higher or 
comparable NHEJ-mediated mutation rates compared to NK-TALENs (Figure 16). The 
mutation rates resulted from NH-TALENs are comparable to that of NN-TALENs in 
most cases. Since the SAPTA program was optimized for the design of NK-TALENs, 
NK-TALENs designed by SAPTA (TALENs targeted to genes other than HBB) result in 
 
Figure 14: TALEN target sites in six different genes. 
Target sequences of nine target sites in six genes. The 5’-flanking T is shown in each nuclease target 
sequence. The G’s are highlighted in orange.  
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mutation rates close to NH- and NN-TALENs. On the other hand, NK-TALENs targeted 
to HBB, which were not designed by SAPTA, sometimes result in less than half of the 
mutation rates from NH and NN. To determine if the different activities of KNH 
TALENs are dose-dependent, we tested activities of S-02/S-05 TALENs, but did not 
observe considerable difference at lower dosages (Figure 17). As expected, if there are 
fewer numbers of G’s in the target sites, for example, in S-116/S-120, C-03/C-04, and F-







Figure 15: T7E1 assay of KNH TALENs at their intended target sites. 
“-” denotes samples treated with an empty TALEN backbone. Numbers below each lane show the 
average percentage of modified alleles (n=3). Arrows indicate specific T7E1 cleavage products. Note 









Figure 17: Activity of KNH TALENs with different doses of nuclease plasmids. 
Different total amount of nuclease plasmids were transfected into HEK293T cells, and T7E1 assay was 
performed to quantify the mutation frequencies (% indels). Error bars, s.e.m. (n=2). 
 
Figure 16: NHEJ-mediated mutation (% indels) of KNH TALENs at their intended target sites. 
NK (blue), NH (red), and NN (green) activity at target sites shown in (a) were measured in HEK293T 
cells. The percentage of G (%G) and number of G (#G) in left and right (L/R) target half-sites are 
indicated below each set of columns. Error bar, s.e.m. (n=3). Asterisks indicate P-values from a two-








Comparing the off-target effect of KNH TALENs 
 We evaluated off-target effect of TALENs containing different G-targeting RVDs 
by investigating the putative off-target sites with sequence similarities to the intended 
Figure 18: Putative off-target sites of TALEN pairs bearing various mismatches. 
Off-target sites corresponding to six pairs of target sequences: S-02/S-05, S-02/S-12, S-02/R-04, S-
116/S-120 (top box), G-122/G-123 (middle box), and G-128/G-42 (bottom box). The 5’-flanking T is 
shown in each target sequence. The mismatched nucleotides between intended targets and off-target 
sites are highlighted in red. The genes associated with these off-target sites are indicated on the left of 
the off-target sequences. 
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sequences. Previous studies compared the off-target activity of NK-, NH-, and NN-TAL 
effectors using artificial targets with A’s in place of G’s(1,50), in order to compare the 
ability of these TALENs to differentiate between nucleotides A and G. Here we compare 
the global, general off-target effect in the endogenous genome by investigating in 
putative sites bearing different mismatches not limited to “G to A mismatch” (Figure 18). 
 The putative off-target sites we identified contain one to five total mismatches 
compared to the intended targets. HBD gene is most similar to the HBB gene, so we used 
it to examine the off-target effect of the four sets of TALEN pairs targeted to HBB. For 
the G-128/G-42 pair designed to target the ATF4 gene, we identified several genomic 
sites with one to three total mismatches using the PROGNOS search tool (65) (Figure 
18). These sites allow us to compare how KNH TALENs tolerate different numbers of 









  We first measured the off-target mutation rates at the HBD gene using T7E1 assay 
in HEK293T cells. Genomic DNAs used to quantify the on-target activity were analyzed 
again for the off-target effect. The four sets of TALEN pairs intended for HBB contain 
three to five total mismatches at the similar HBD gene (Figure 18). T7E1 assay for these 
Figure 19: Off-target activities of NK-, NH-, and NN-TALEN pairs bearing various mismatches. 
(a-c) Off-target % indels of HBB-targeting KNH TALENs at the HBD gene measured by the T7E1 
assay. “-” denotes samples treated with an empty TALEN backbone. Numbers below each lane show 
the average percentage of modified alleles (n=3). Arrows indicate specific T7E1 cleavage products. (d) 
Top, T7E1 assay showing the off-target % indels of the HBB-targeting KNH TALENs at the similar 
site in the HBD gene. Bottom, percentages of TALEN-induced mutated sequences at the HBB on-
target site and HBD off-target site detected by Sanger sequencing. (e-f) Percentages of mutated 
sequences of NK- (blue), NH- (red), and NN-TALENs (green) at their intended target sites and off-
target sites measured by SMRT sequencing. The on-target activities are the first set of columns from 
the left. The insert in (f) is a zoom-in view of the three off-target sites. NN-low (light green) in (f) 
indicates activities associated with a lower dose of plasmids transfected to match the on-target activity 
of NH-TALENs. Error bar, 95% confidence interval (Wilson method). 
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TALENs revealed different levels of off-target mutagenesis at the HBD locus (Figure 
19a-d). The on- and off-target modification frequencies resulted from S-02/R-04 pairs 
were confirmed by Sanger sequencing of PCR products cloned into plasmid vectors 
(Figure 19d). Three out of four NN-TALENs resulted in substantial mutation rates 
(Figure 19a, b, and d); one NH-TALENs showed considerable off-target cleavage (Figure 
19a); none of the four NK-TALENs was found to have off-target effect at the HBD. 
Mismatch of the 5’ flanking T (position 0) may be a major contributor to the lack of off-
target cleavage from S-116/S-120 TALENs, since 5’-T was speculated to be a potent 
discriminant between highly similar sites (66). Mismatches at both the N-terminus and C-
terminus seem to contribute to the discrimination between similar sites. Compared to S-
12, S-05 has one additional mismatch at the N-terminus, while R-04 has one extra 
mismatch at the C-terminus (Figure 18). When paired with the same left TALEN site S-
02, NN- and NH-TALENs of both S-05 and R-04 showed reduced off-target mutagenesis 
compared to S-12 at the HBD locus (Figure 19). The additional mismatch at the N-
terminus in S-05 resulted in more prominent decrease of the off-target effect, which is 
consistent with previous publications indicating that N-terminal repeats have more impact 
on TALE binding to DNA(67,68). 
 Additional off-target sites for TALENs targeted to the CCR5 and ATF4 genes 
were analyzed by Single molecule real time (SMRT) deep sequencing for a higher 
detection sensitivity (Figure 19e, f). To account for the variance in on-target activity, we 
calculated an “off-target factor” by normalizing the off-target activity with each TALEN 
pair at each site against the on-target activity of the TALEN pair (Table 1). NK-TALENs 
displayed overall less off-target effect: among the eight off-target sequences analyzed, 
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one NK-TALEN pair, three NH-TALEN pairs, and five NN-TALEN pairs have off-target 
factors >0.1, which indicate considerable off-target activity higher than 10% of the on-
target activity. NH-TALENs have low off-target effect similar to NK-TALENs, except 
for the S-02/S-12 NH-TALENs (Figure 19a), which have significantly higher on-target 
activity compared to NK-TALENs. With similar on-target mutation rates, the S-02/S-12 








 Nucleotide mismatch  Off-target factorb Detection
MethoddTotal Left Right  NK NH NN NN-lowc 
S-02/S-05 HBD 4 2 2 0 0 0.249 T7E1
S-02/S-12 HBD 3 2 1 0 0.534 1.103 T7E1
S-02/R-04 HBD 4 2 2 0 0 0.604 Sanger
S-116/S-120 HBD 5 4 1 0 0 0 T7E1
G-122/G-123 CCR2 2 2 0 0.182 0.107 0.329 SMRT
G-128/G-42 USP28a 1 1 0 0.064 0.106 0.104 0.113 SMRT
G-128/G-42 RNF157 2 1 1 0.017 0 0.091 0.048 SMRT
G-128/G-42 CTAG1Ba 3 3 0  0.005 0 0.014 0.009 SMRT
 
a. The genes indicated are located closest to these off-target sites in intergenic regions. 
b. Ratio of the off-target to on-target modification frequency. Non-detectable off-target activity is marked 
as a zero. Off-target factors above 0.1 are highlighted by gray background. 
c. Samples with a lower dose of plasmids transfected to match the on-target activity of NH-TALENs. 
d. Methods used to quantify the gene-modification frequencies include T7E1 assay, Sanger sequencing, and 





 NN-TALENs constantly resulted in similar or higher off-target modification 
frequencies compared to NK and NH. The higher off-target effect associated with NN-
TALENs cannot be explained by its higher on-target activity, since NN-TALENs used 
for off-target analysis always have similar on-target activity compared to NH- or NK-
TALENs. Neither can this higher off-target effect be readily explained by less 
differentiation between “G” and “A” bases, as only one mismatch among these eight off-
target sequences is a “G to A mismatch” (CCR2 locus). Lower dose of G-128/G-42 NN-
TALENs were transfected into HEK293T cells to reduce the on-target activity to match 
that of NH-TALENs, but the off-target effect from the NN-TALENs could not be 
eliminated using a lower dose (Figure 19f, Table 1).   
 We also investigated putative heterodimeric (left and right TALENs) and 
homodimeric (left paired with left TALENs, or right paired with right TALENs) off-
target sites containing five to 14 mismatches to TALENs intended for CXADR, CFTR, 
AAVS1 (PPP1R12C), and ATF4. For these putative sites, no off-target cleavage 
significantly higher than the mock-transfected sample was identified using SMRT deep 
sequencing or T7E1 assay ( 









NN-TALENs achieve higher rates of homologous recombination (HR) 
 We measured gene-targeting frequencies of different TALENs by providing a β-
Ubc-GFP donor vector with ~1 kb homology arms 5’ and 3’ of the TALEN target sites in 
the HBB gene. A Ubc-GFP cassette was included between the 5’ and 3’ homology arms, 
thus that GFP will be stably expressed upon successful HR(69). TALEN pairs targeted 
close to the sickle mutation were co-transfected with the β-Ubc-GFP donor vector into 
K562 cells, and the levels of HR were determined by quantifying stable integration of 
Ubc-GFP in cells (Figure 21). 
 
Figure 20: Off-target analysis for homo-dimeric sites of ATF4-targeting TALENs. 
(a) Homo-dimeric off-target sites for ATF4-targeting TALENs. The mismatched nucleotides are 
highlighted in red. The 5’-flanking T is also shown. (b) T7E1 assay of ATF4-targeting NN-TALENs at 








 All NN-TALENs achieved higher gene-targeting rates compared to NK- and NH-
TALENs for the same target (Figure 22a). NN-TALENs of S-02/S-12 and S-02/R-04 
both led to substantially higher gene-targeting efficiency compared to other TALENs. 
Surprisingly, the gene-targeting rates do not correlate well with the NHEJ-mediated 
mutagenesis from the same TALENs (Figure 22b). The NH- and NN-TALEN pairs with 
Figure 21: Percentages of GFP-positive cells after transfection of HBB-targeting TALENs and β-Ubc-
GFP donor plasmid. 
The percentages of GFP+ cells measured by flowcytometry were normalized to the GFP+ cells on day 
1 after transfection to account for varying transfection efficiency. 
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NHEJ-mediated mutation rates around 60% (S-02/S-05, S-02/S-12, S-116/S-120) showed 
drastically different gene-targeting frequencies ranging from 6% to 22%. Even TALENs 
with the same target sequence and only different by the G-targeting RVD have poor 
correlation between NHEJ and HR. For example, the NK-, NH-, and NN-TALENs of S-
02/R-04 have similar levels of NHEJ-mediated mutagenesis (Figure 16b), but very 
different gene-targeting rates (Figure 22a). Further study is needed to determine factors 








Figure 22: Gene targeting efficiency of NK-, NH-, and NN-TALEN pairs at the endogenous HBB 
locus. 
(a) Gene targeting of β-Ubc-GFP to the HBB locus in K562 cells using different TALEN pairs. The 
percentages of stably integrated EGFP were normalized to transfection efficiency. “—” indicates cells 
transfected with the β-Ubc-GFP targeting vector alone. Error bar, s.e.m. (n=3). (b) Little correlation 
between gene-targeting frequency and NHEJ-mediated mutation frequency of TALEN pairs. Gene-
targeting frequencies from (a) are plotted against the NHEJ-mediated mutation frequencies of TALEN 
pairs targeted to HBB. The R squared value of all TALENs in the plot is also indicated. 
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applications. 
3.3  Discussion 
 The activity and specificity of TALENs directly correlate with the efficacy and 
safety of genome engineering applications, especially clinical use of nucleases, and thus 
need to be well characterized. Finding a highly efficient yet specific RVD to recognize 
the nucleotide G is a useful approach to improve TALEs and TALENs. The G-
recognizing RVD NK employed by TALEs or TALENs was previously shown to target 
G specifically but with considerably less activity compared to the RVD NN(1,24,50,68). 
Studies of TALEs revealed that the RVD NH may yield increased specificity for 
recognizing G compared to NN, while maintain relatively high activity compared to NK 
(1,50). However, activity and specificity of the NH RVD has not been previously 
demonstrated in TALENs. 
 Although NN-TALEN specificity in endogenous genomes was evaluated by a 
number of studies (25,32,66,70-72), very few provided a comparison with NK-TALENs 
(30,65). There has not been any publication comparing activity or specificity of TALENs 
employing all three G-targeting RVDs, NK, NH, and NN. Other than a simple 
differentiation between G and A, a more complete and general specificity profile of 
TALENs constructed with different G-targeting RVDs needs to be defined and compared.  
 Here we compared the on- and off-target mutagenesis activity of nine sets of NK-, 
NH-, and NN-TALENs, and also evaluated the ability of four sets that recognize the HBB 
loci to trigger gene-targeting through the HR pathway. TALENs constructed with the 
RVD NH induced NHEJ-mediated gene modification comparable to or higher than those 
with NK, and the frequencies associated with NH RVD are similar to those with the 
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highly active NN RVD, except for the NH-TALEN pair targeted to the ATF4 gene 
(Figure 16b). Despite the high NHEJ-mediated mutation rates resulted from NH-
TALENs, their ability to trigger HR is still not as high as the NN-TALENs (Figure 22a). 
Interestingly, we found that the indel spectra of KNH TALENs are different, especially 
that the NH-TALENs seem to induce large deletions more frequently than NK- and NN-
TALENs (Figure 23). Five out of the nine NK-TALENs tested have on-target mutation 
rates significantly lower compared to corresponding NH- or NN-TALENs, confirming 
that the NK RVD is less efficient in binding to guanine (Figure 16b). However, NK-
TALENs still showed overall less off-target effect, and good discrimination against off-
target sites with ≥3 total mismatches (Table 1). NH-TALENs are also able to eliminate 
off-target effect with similar sites containing ≥3 total mismatches (Table 1), except for 
the S-02/S-12 off-target site at HBD where two of the three mismatches are bound by the 
C-terminus of TALENs, which were previously shown to be less specific(67). NN-
TALENs could not sufficiently differentiate similar off-target sites with up to four total 
mismatches (Table 1). We did not find any off-target cleavage above background signal 
for any of the TALENs at genomic sites with ≥5 total mismatches (Table 1, Figure 20, 
and  









 In summary, if a high HR rate is desired, NN-TALENs would be the first choice, 
but the off-target effect should be carefully avoided by selecting target sites with the most 
similar sites in the genome containing at least five total mismatches. If high specificity is 
desired, NK-TALENs are preferred, which can differentiate sites with ≥3 total 
mismatches. Mismatches in the off-target sites located close to the N-termini of TALENs 
 
Figure 23: Mutation spectra of KNH TALENs targeted to CXADR. 
The net lengths of indel (- deleted bp + inserted bp) were analyzed using SMRT sequencing with a 
709-bp amplicon in the CXADR gene. Only sequencing reads showing insertion and/or deletion were 
included in this graph. When the net indel length is zero, there is still insertion and deletion in the read, 
but the number of deleted bases equals the number of inserted base. (a, b] means > a and ≤ b. The y 
axis (percentage of total indels) is the number of reads at a specific net length divided by the total 
number of indel reads for that specific pair of TALENs. 
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seemed to be better discriminated by TALENs. NH-TALENs can achieve high levels of 
NHEJ-mediated mutation, and adequately minimize off-target effect if mismatches are 
not located near the C-terminal end of TALENs. Our results also showed a disconnection 
between NHEJ-mediated mutation frequency and HR-mediated gene-targeting frequency. 
It will be interesting to see what elements contribute to the different pathway choice 
following TALEN cleavage of DNA. 
3.4  Materials and methods 
Assembly of TALENs 
 TALENs were assembled using a hierarchical Golden Gate method (23) with 
repeat plasmids containing RVDs HD, NI, and NG to recognize C, A, and T, 
respectively. To recognize G, RVDs NK, NH, or NN were constructed into NK-, NH-, 
and NN-TALENs, respectively. The process of assembly and sequence confirmation was 
as describe before (3). TALEN backbone vector was the same as in a previous study (3). 
Complete amino sequences of TALENs are included in Appendix A.  
T7E1 mutation detection assay to determine mutation frequencies at endogenous 
gens 
 The NHEJ-mediated genetic mutation resulted from TALEN pairs was quantified 
by the T7E1 assay as previously described (3).  Briefly, 40,000 HEK293T cells were 
seeded in a well of a 24-well plate, and transfected 24 hrs after seeding with 500 ng of 
each TALEN plasmid and 10 ng of pEGFP plasmid using FuGene HD (Promega, 
Madison, WI).  72 h after transfection, cells were harvested and genomic DNAs were 
extracted using QuickExtract DNA extraction solution (Epicentre, Charlotte, NC). 
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Genomic loci were PCR-amplified using AccuPrime Taq DNA Polymerase High Fidelity 
(Life Technologies, Carlsbad, CA) as described before (3). PCR products were purified 
using Ampure XP (Beckman Coulter, Pasadena, CA) following manufacture’s protocol 
using a Biomek 3000 station (Beckman Coulter, Pasadena, CA). T7E1 assays were 
performed as described (3). Primers used for this assay are listed in Table 9 (Appendix 
A). 
Sanger sequencing to determine genetic mutations resulted from TALENs 
 PCR products described in the T7E1 assay above were cloned into plasmid 
vectors using TOPO TA Cloning Kit for Sequencing (Life Technologies, Carlsbad, CA) 
or Zero Blunt TOPO PCR Cloning Kit (Life Technologies, Carlsbad, CA), following 
manufacturer’s instructions. Plasmid DNAs were purified and subjected to Sanger 
sequencing using a M13F primer (5’-TGTAAAACGACGGCCAGT-3’). Plasmid 
sequences from a PCR product were aligned to the wild-type reference sequence. To 
calculate the percentages of indels, any plasmids with insertions or deletions compared to 
the reference sequence were counted, and divided by the total plasmids sequenced. 
Identification of putative off-target sites and SMRT sequencing to quantify the 
mutation rates 
 Potential off-target sites for the TALENs were chosen from the PROGNOS RVD 
and Homology rankings to contain a mixture of the top-ranked sites from both 
algorithms(65). Genomic DNA was extracted from HEK293T cells 3 days post-
transfection with TALENs or pUC plasmid. PCR primers designed by PROGNOS (Table 
8 in Appendix A) were used to amplify the predicted off-target loci and amplicons were 
sequenced using the RS SMRT technology (Pacific Biosciences) exactly as previously 
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described(65). The results were analyzed by custom Perl scripts to identify reads 
containing evidence of NHEJ(65).  
Measuring the frequencies of homologous recombination (HR) stimulated by 
TALENs 
 K562 cells were maintained in HyClone RPMI 1640 (GE Healthcare, Pittsburgh, 
PA) supplemented with 10% bovine growth serum, 100 U/ml penicillin, 100ug/ml 
streptomycin, and 2mM L-glutamine, filtered sterilized. K562s were transfected via 
nucleofection (Lonza, Basel, Switzerland) using program T-016 and nucleofection buffer 
containing 100mM KH2PO4, 15mM NaHCO3, 12mM MgCl2, 8mM ATP, 2mM glucose, 
pH 7.4. 
 106 K562 cells were transfected with 1 µg left TALEN plasmid and 1 µg right 
TALEN plasmid and 5 µg β-Ubc-GFP donor plasmid (69). Cells were split and analyzed 
regularly via FACS Accuri C6. Percentages of GFP-positive cells were measured over 
time until a plateau was reached (around two weeks). The amount of stably integrated 
GFP cassette was determined using the end-point GFP-positive cell percentages. Stable 
fluorescence achieved is then normalized to transfection efficiency (percent GFP-positive 




CHAPTER 4: DEVELOPMENT OF A NEW DESIGN TOOL FOR 
IMPROVING TALEN ACTIVITY 
 Transcription activator-like effector nucleases (TALENs) have become a 
powerful tool for genome editing due to the simple code linking the amino acid 
sequences of their DNA binding domains to TALEN nucleotide targets. While the initial 
TALEN design guidelines are very useful, user-friendly tools defining optimal TALEN 
designs for robust genome editing need to be developed. Here we evaluated existing 
guidelines and developed new design guidelines for TALENs based on 205 TALENs 
tested, and established the Scoring Algorithm for Predicting TALEN Activity (SAPTA) 
as a new online design tool. For any input gene of interest, SAPTA gives a ranked list of 
potential TALEN target sites, facilitating the selection of optimal TALEN pairs based on 
predicted activity. SAPTA-based TALEN designs increased the average intracellular 
TALEN monomer activity by >3 fold, and resulted in an average endogenous gene 
modification frequency of 39% for TALENs containing the repeat variable di-residue NK 
that favors specificity rather than activity. It is expected that SAPTA will become a 
useful and flexible tool for designing highly active TALENs for genome editing 
applications. SAPTA can be accessed via the website at 
http://baolab.bme.gatech.edu/Research/BioinformaticTools/TAL_targeter.html. 
4.1  Introduction 
 Transcription activator-like effectors (TALE) are a family of DNA binding 
proteins, discovered in the plant pathogen Xanthomonas (19-22). Each DNA-binding 
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domain of TALE contains a variable number of 33-35 amino-acid repeats that specify the 
DNA-binding sequence primarily through their 12th and 13th repeat-variable di-residues 
(RVDs) (19). Each RVD specifies one nucleotide with minimal context dependence 
(20,22,23). A transcription activator-like effector nuclease (TALEN) targets a specific 
DNA sequence through designing a set of RVDs that are flanked by modified N- and C-
termini (24,28) and linked to a FokI nuclease domain (15,26,27). When a pair of 
TALENs binds to their specific half-sites with the correct orientation and spacing to 
allow the nuclease domains to dimerize, the intervening sequence is cleaved. TALENs 
have been used to edit genomic DNA sequences in a variety of biological systems, 
including human cells, rats, zebrafish, nematodes, and plants (23-25,28-32). 
 Although the codes of nucleotide recognition by RVDs have been established and 
five design guidelines were derived from naturally occurring TALE target sites (23), 
these guidelines are not sufficient to provide discrimination against suboptimal target 
sites. Recent evaluation of the existing design guidelines using hetero-dimeric TALEN 
pairs (2) revealed that the activities of the TALEN pairs varied markedly; however, no 
significant correlation between guideline violations and TALEN activities was found, 
possibly because the assessment was on TALEN pairs rather than individual TALEN 
monomers. Existing design tools (such as TALE-NT 2.0) intend to help users to filter 
gene sequences based on simple qualitative criteria; however, they often result in a large 
number (hundreds to thousands) of potential TALEN target sites with activities varying 
over a wide range, clearly indicating the need for a new design tool that selects high-
activity target sites for TALENs. 
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 We have developed a new online design tool, Scoring Algorithm for Predicting 
TALEN Activity (SAPTA), to quantitatively evaluate target sites by assigning scores that 
reflect predicted TALEN activities, thus allowing end users to select the optimal target 
sites among many possible choices within a given gene segment through the use of 
SAPTA at http://bit.ly/SAPTA. The SAPTA prediction is based on experimentally 
measured activities of 130 TALEN monomers constructed with the guanine-targeting 
RVD NK (NK-TALENs). Although NK-TALENs generally have higher specificity 
compared with TALENs containing the guanine-targeting RVD NN (NN-TALENs) 
(1,24), their activity level is usually lower than NN-TALENs. Therefore, it is important 
to increase the activity level of NK-TALENs for effective gene editing.  
 To evaluate the performance of SAPTA, 75 additional NK-TALEN monomers 
were tested. We found that SAPTA-designed TALENs have significantly higher activity 
compared with TALENs designed following existing guidelines. Specifically, SAPTA-
based TALEN designs increased the average intracellular TALEN monomer activity by 
>3 fold, achieved a larger percentage of highly active TALENs compared to that in 
previous studies (2,4,7), and resulted in an average endogenous gene modification 
frequency of 39% for TALENs containing the repeat variable di-residue NK that favors 
specificity rather than activity. Furthermore, we showed that SAPTA can also be used to 
design NN-TALENs that have improved activity.  
4.2  Results 
Design and test of TALENs in the Training Set 
  To establish the correlation between TALEN activity and design variables, we 
first performed PCR-based, modified single-strand annealing (SSA) assays to quantify 
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the activity of individual TALEN monomers in cleaving extrachromosomal plasmids 
with a homo-dimeric target site and a fixed 17-bp spacer. This assay bypassed the effect 
of genomic context at endogenous gene targets that may obscure the correlation between 
TALEN activity and design variables. We quantified each TALEN monomer’s SSA 
activity or % SSA, defined as the percentage of SSA-repaired cleavage products in 
HEK293T cells co-transfected with plasmid encoding the TALEN monomer and the 
target plasmid (Figure 11). The validity range of this method was determined by 
establishing a standard curve that indicated a near-linear correlation between the 
percentage of SSA-repaired PCR products measured and the fraction of pEGFP (identical 
to a SSA-repaired plasmid) in the co-transfection mix up to ~50% (Figure 24).  
 We assembled and measured the SSA activities of 130 TALEN monomers 
targeting a variety of sequences (3). All of the 130 TALENs were constructed using 
RVDs NK for G, HD for C, NI for A and NG for T, and with a 5’-T preceding each 
TALEN target half-site. NN-TALENs generally have higher activity, but may lead to 
lower specificity compared with NK-TALENs (1,24). We therefore used 130 NK-
TALENs as our Training Set to facilitate the design of highly active NK-TALENs.  We 
compared the on- and off-target activities of a few sets of TALENs that differed only in 
the G-targeting RVDs (NN vs. NK). Transfecting cells with plasmids for NN-TALENs 









 TALENs in the Training Set were designed by considering two major groups of 
TALEN target sequences. One group contains TALEN target sequences that were 
selected from output lists for several gene segments screened by the old version of 
TALEN Targeter (23). The selection of these TALEN target sites was somewhat 
arbitrary, except that they should be located near the site of interest. The other TALENs 
targeted artificial sequences that we specifically varied to test the effect of certain design 
variables, including mutating specific nucleotides at positions near the 5’ and 3’ of the 
target sequence, varying the numbers of maximum consecutive A’s and G’s, and 
increasing the percentages of certain nucleotides in the first and last five nucleotides of 
the target sequence. TALENs of the second group were labeled as “n/a” in the column of 
“Target gene” in Supplementary Table S4 of reference (3). Together, the Training Set 
 
Figure 24: A standard curve validating the modified SSA assay measuring TALEN monomer activity 
in HEK293T cells. 
Error bars, s.e.m. (n=3). 
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includes 130 TALEN monomer target sequences, 74 for targeting HBB, 7 for CFTR, 2 for 
CXADR, 4 for ERCC5, and 43 with artificial sequences (n/a). The effects of neighboring 
nucleotides were not considered here since no neighboring effects have been reported in 
previous studies (22,23). If future studies identify any neighboring effect, additional 
variables (for example, product of two terms) will be introduced into the SAPTA function 
and the parameters re-optimize. 
 The Training Set also covers reasonably large ranges for each design variable we 
tested, including 14-30 repeat arrays, 0-56% A, 14-53% C, 0-45% G, 4-56% T; 0-80% A, 
C, G, and T in the first five nucleotides; 0-80% A and C in the last five nucleotides, and 
0-100% G and T in the last five nucleotides. Due to practical considerations, it is not 
possible to test all possible combinations of nucleotides throughout the DNA binding 
domain of a TALEN. We chose the Training Set so that these TALENs cover a wide 
range of the design variables considered, with detectable and varying activities.  
 We tested the activities of 37 TALEN pairs from the Training Set at their 
endogenous gene targets using the T7 endonuclease I (T7E1) assay in HEK293T cells 
(Figure 25). These 37 TALEN pairs contain all combinations of active TALEN 
monomers in the Training Set separated by spacers ranging from 15 to 30 bp in targeted 
human genes. TALEN pairs with spacers smaller than 14 bp and higher than 19 bp 
showed no detectable gene-modification activity despite high SSA activities for some of 
the TALEN monomers. The activities of TALEN pairs with optimal spacers (defined as 
14-19 bp) were compared with their “composite SSA activities” which integrated left and 
right TALEN monomer activities (see ‘Materials and methods’ section) (Figure 26). We 
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found that TALEN pairs from the Training Set having observable gene modification 
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Figure 25: T7E1 assay results for 37 unselected, training- set TALEN pairs. 
Detectable activity in the T7E1 mutation detection assay was observed for five of the 37 TALEN pairs 
in the training set. Activities greater than 1% are shown as percentage of indels below the 
corresponding gel lane. Each activity was calculated from 3 independent experiments. The 37 pairs 
include (a) 32 pairs targeting the β-globin (HBB) gene (b) 3 pairs targeting the CFTR gene and (c) 2 
pairs targeting the ERCC5 gene. Lane headings indicate the left and right TALEN index numbers. “-” 
denotes the control lane where samples were treated with an empty TALEN backbone. Arrows 







 Three TALEN pairs (indicated with asterisks in Figure 26) showed no gene-
modification activity, although they had >30 composite SSA activities. Sequencing 
results of the target sites showed no polymorphism, and the cellular expression levels of 
these TALENs were similar to other TALENs (with different lengths of repeat arrays) 
(Figure 27), suggesting that the lack of detectable gene-modification activity was not due 
to target variation or low protein expression. Further investigation showed that the two 
 
Figure 26: Comparison between composite SSA activity and the endogenous gene modification rates 
of TALEN pairs. 
TALEN pairs from the training set with optimal range of spacer are ranked by their composite SSA 
activities (grey columns) from low to high (left to right). Endogenous gene modification rates of the 
corresponding TALEN pairs quantified by T7E1 assay are shown as black columns. Both SSA activity 
and endogenous gene-modification activity were measured in HEK293T cells. Dashed line indicates 
composite SSA activity of 30, which is achieved when both left and right TALEN SSA activities are 
~10%. Asterisks indicate three TALEN pairs with >30 composite SSA activities but no gene-
modification activity. Error bars, s.e.m. (n=3). 
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ERCC5-targeting pairs, J-03/J-04 and J-09/J-10, both have high cellular activity with 
extrachromosomal plasmid targets. Bisulfite sequencing of this locus revealed methylated 
cytosines in all the CpG di-nucleotides in the target sequences of these two pairs, 
consistent with previous studies showing that methylated cytosines blocked the binding 
of TAL effectors (TALEs) or TALENs (7,74,75). Since no CpG site is present in the 
target sites of the TALEN pair S-21/S-23, undetectable gene-modification activity for this 
pair may be due to the long repeat array of S-21 (29 repeats). The large size of TALEN 






Figure 27: Western blot analysis of TALENs with 14.5 to 29.5 repeats. 
These TALENs had a range of monomer activities, but similar expression levels when transfected into 
HEK293T cells, as for the Single Strand Annealing assay (Material and Methods). Cell lysates were 
collected two days after transfection, separated on NuPAGE Novex 4-12% Bis-Tris gels (Life 
Technologies) and blotted with antibodies.  Expression levels were determined using antibodies to the 
FLAG tag (at the N-terminus of each TALEN). Antibodies to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were used as the internal control. 
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Comparison with previously published guidelines (2,23) 
Base identities at 5' 
(Pos. 1), 2nd nt.  
from 5' (Pos. 2), 
and 3' ends (23) 
No T at Pos. 1 
No A at Pos. 2 
T at the 3' end 
G at Pos. 1 
T at Pos. 2 
G at 3’ end 
+ 
Some specific 
nucleotides at these 




A 31 ± 16%              0% 
+++ 
Choose target sequences 
with a large percentage 
of Cc 
C 37 ± 13%            53% 
G 9 ±  8%            10% 
T 22 ± 10%            37% 
Length of target 
sequence (2) 
 
15-20 bp 15-25 bp + 
The length of a target 
sequence should be 
15~25 bpc 
Spacer length (2)  16-19 bp 14-19 bpd n/a 
Spacer length should be 
14~19 bp 
      
New design guidelines 
Base composition 
of the first 5 nt 
  A      ≤20% 
++ 
The first 5 nt of the 
target sequence should 
contain a large %Cc 
  C   60-80% 
  G Not decisive 
  T Not decisive 
       
 
Base composition 
of the last 5 nt 
  A      ≤60% 
++ 
The last 5 nt of the target 
sequence should contain 
a large %Tc 
  C Not decisive 
  G      ≤60% 
  T 80-100% 
       
Max. num. of 
consecutive A’s    
≤3 + 
Longer stretches of A’s 
can lower the activity 
Max. num. of 
consecutive G’s       
≤3 ++ 
Longer stretches of G’s 
can lower the activity 
 
a Optimal value shows the value of a certain variable that maximizes its score contribution (defined as the 
sum of all contributions from the variable), with the constraint that the value of this variable should be 
within the range in the Training Set. 
b Relative importance of each design feature was rated by its magnitude of contribution to the score. 
c Target sequence refers to a half-site targeted by a TALEN monomer, excluding the 5’-T immediately 
before the 5’ end of the half-site. 










Figure 28: Development and evaluation of SAPTA using 205 NK-TALEN monomers. 
(a) Correlation between predicted SAPTA scores (y-axis) and intracellular TALEN-monomer activity 
(x-axis) measured by the modified SSA assay in HEK293T cells. Error bars, s.e.m. (n=3). (b) 
Categorization of TALENs in the training set and test set using 10% SSA activity as a cut-off for high 
activity. TALENs with low scores (≤10) and high scores (>10) are evaluated separately. (c) The 
percentages of TALENs predicted by SAPTA scores being false negatives (score ≤10 
but %SSA >10%) and true negatives in the low score group, and false positives (score >10 but %SSA 
≤10%) and true positives in the high score group. 
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SAPTA: Scoring Algorithm for Predicting TALEN Activity 
  The SAPTA algorithm, which contains a total of 30 variables (see detailed in the 
‘Materials and methods’ section), was established based on the measured SSA activities 
of 130 NK-TALENs in the Training Set. The SAPTA variables were chosen to evaluate 
the existing design guidelines (2,23) and to establish new design guidelines (Table 2). 
Without any pre-assumption, based on the measured SSA activities of TALENs in the 
Training Set, the parameters in the SAPTA algorithm were solved using linear modeling 
in the R statistical software (version 2.15.2) (76), which gave rise to an excellent 
correlation with the Training Set (R2 = 0.81) (Figure 28a).  Consequently, SAPTA is able 
to provide a numerical score that estimates TALEN activity (high scores indicate high 
activity).   
 Using SAPTA, we evaluated the TALEN design guidelines proposed by Cermak 
et al.(23), Reyon et al. (2), and Streubel et al. (1), and established new design guidelines 
(Table 2, Figure 29, and Figure 30). Specifically, the strong bias for C in the optimal 
nucleotide percentages calculated using the SAPTA agrees well with previous studies 
indicating that the RVD HD for C leads to high DNA-binding affinity (1,50). The optimal 
length of target sequences and spacer length identified using SAPTA are consistent with 
design guidelines proposed by Reyon et al. (2). In addition, our experimental results 
indicated that long stretches of A’s or G’s decrease the SSA activity, as reflected in 
SAPTA predictions (Figure 29), especially with >3 consecutive G’s. This conclusion 
derived by SAPTA is also consistent with the relatively low binding affinities of RVDs 









 By examining the SAPTA function, we also found that the nucleotide percentages 
of the first and last five nucleotides of target sequences are important. We varied the first 
five nucleotides systematically to sample all possible combinations (4^5=1024), followed 
by a constant sequence “AACCTCTGGGTCCAA” to create a 20-nt sequence. SAPTA 
scores of these 1024 sequences that only differ in the first 5 nucleotides were recorded, 
except for those with variable values outside the ranges of Training Set. Box-and-whisker 
plots show the sets of scores recorded at 0-80% or 0-100% of each nucleotide (Figure 
30). The upper limits of nucleotide percentages were determined by limits of the Training 
Set. Similarly, the last five nucleotides were varied to create 1024 sequences, preceded by 
a constant sequence “CACAGAACGTCAGGT”. The score analysis was performed the 
   
Figure 29: Contribution of target length (left) and long stretches of A’s and G’s (right) to SAPTA 
scores. 
The graphs were plotted using functions corresponding to these variables from SAPTA algorithm (3) 
explained in the “materials and methods” section. 
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same as for the first five nucleotides. In general, high TALEN scores are achieved with a 















 This new design guideline was experimentally confirmed by specifically varying 
sequences at the 5’ and 3’ ends of TALENs in Test Set 1 (3), which contains 12 
TALENs. To minimize the change of other variables, in Test Set 1, TALENs were 
designed by re-arranging nucleotide positions in the original target sequences without 
changing the overall base compositions and lengths. Five nucleotides containing 80% of 
C’s from the 3’ ends of TALENs labeled F-05 and S-98 were switched with nucleotides 
at their 5’ ends (Figure 31). This switch resulted in large percentages of C’s at their 5’ 
ends and the removal of C’s from the 3’ ends, thus increasing their scores and SSA 
activities. Five nucleotides containing 80% of T’s from the 3’ ends of TALENs labeled J-
03 and J-09 were switched with five nucleotides in the middle or their targets (Figure 31). 
This switch resulted in large percentages of C’s at 3’ ends and the removal of T’s from 
the 3’ ends, thus lowering the scores and SSA activities. When the five nucleotides at the 
5’ ends were replaced by 80% C’s originally located at the 3’ ends, the overall C 
composition remained the same, but the SSA activities increased. When the 3’ T’s were 
replaced with 60% or 80% of C’s, while the overall base compositions stay unchanged, 
the SSA activities decreased (Figure 31). The increase in the percentage of C’s at the 5’ 
end is accompanied by changes at the 3’ end due to the base swaps (Figure 31e), and both 
changes may cause alterations in TALEN activity. However, according to SAPTA 
predictions, changes at the 3’ end from 80% C to 0% or 20% C would have minimal 
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effect on SAPTA scores (Figure 30). Therefore, our analysis suggests that the increase in 







Figure 31: Experimental validation of new design rules on the base compositions in the first and last 




 SAPTA, a user-friendly online search tool was established to help researchers 
identify optimal TALEN target sites within a selected DNA sequence.  The DNA 
sequence of interest, together with the ranges of acceptable target and spacer lengths are 
entered into the web interface, which then outputs a ranked list of SAPTA scores for each 
TALEN pair, together with the corresponding target sequences and the nucleotide 
preceding each target half-site (2,23). For each pair of TALENs, a single numerical 
value—the composite SAPTA score—is defined based on the scores of the left and right 
TALENs in a way that favors pairs with balanced left and right scores (see ‘Materials and 
methods’ section).   
 To demonstrate that the use of SAPTA improves the design of NK-TALENs, we 
employed SAPTA to design 63 additional NK-TALEN monomers that form Test Set 2 
(3), with SAPTA scores ranging from 5.3 to 39.1 and measured their SSA activities. 
Specifically, the target sites for TALENs in Test Set 2 were determined by using the 
SAPTA online tool to search 19 gene segments with TAL arrays (DNA binding domains) 
of 14 to 25 repeats, and spacer lengths from 14 to 19 bp. TALEN pairs with high 
composite scores ranked by the online tool were chosen. We mostly selected SAPTA-
designed TALEN monomers with SAPTA scores >10.0, since TALENs with SSA 
activities >10% are likely to result in gene-modification activity (Figure 26). Based on 
SSA measurements, the average SSA activity of TALENs in Test Set 2 was 27.2%, 
compared with 8.6% in the Training Set. Furthermore, we found that 86% of NK-TALEN 
monomers in Test Set 2 had >10% SSA activity, compared with only 33% in the Training 
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Set (Figure 32). The resulting P-value of 2.70X10-12 suggests that the large frequency of 









 Most TALENs in the total Test Set (the combination of Test Set 1 and Test Set 2) 
had SSA activities that correlated with their SAPTA scores, especially those with 
cleavage activities within the range of the Training Set (Figure 28a). The relatively low 
R2 (0.47) for the Test Set is largely due to the 12 TALENs that had SSA activities much 
higher than those in the Training Set (maximum 30% SSA activity), thus could not be 
 
Figure 32: TALEN-monomer activity distribution was substantially improved in the Test Set 2 
compared to the Training Set. 
The percentages of TALENs with SSA activity ≤10 and >10 are shown above each graph. The two-
sided P-value determined by Fisher’s exact test is shown on top. 
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modeled accurately by SAPTA. However, as shown in Figure 28, SAPTA predictions for 
TALENs in the Test Set only had 15% “false positive” rate, defined as the ratio of the 
number of TALENs with low (≤10%) SSA activity in the high score group (score >10), 
divided by the total number of high score TALENs (Figure 28b, c). Similarly, the “false 
negative” rate is defined as the ratio of the number of TALENs with high (>10%) SSA 
activity in the low score group (score ≤10), divided by the total number of low score 
TALENs. The relatively high (50%) false negative rate for TALENs in the Test Set might 
be due to the small sample size (Figure 28b, c).  However, this should not significantly 
affect SAPTA usage, since users typically select the highest scoring TALENs in a region 
for further testing, and having activities higher than predicted scores will not negatively 
impact effective TALEN designs. 
Validation of SAPTA with NK- and NN-TALEN pairs targeting endogenous genes 
  To quantify the gene-modification activities of SAPTA-designed NK-TALENs, 
we examined 24 NK-TALEN pairs from Test Set 2 targeted to 15 human genes  (see 
Supplementary Table S5  of reference (3) for details) by co-transfecting HEK293T cells 
with the two plasmids encoding each TALEN pair, and quantified the gene modification 
rates in the intended target regions using the T7E1 assay (Figure 33 and Supplementary 
Table S5  of reference (3)). The other TALEN pairs formed by TALEN monomers in the 
Test Set 2 were not tested either because the corresponding target loci could not be 
specifically amplified due to the presence of repetitive sequences, or due to the fact that 
they were targeted to non-human genes. Single Molecule Real Time (SMRT) sequencing 









 We found that the majority of NK-TALEN pairs designed by SAPTA were highly 
active: the average mutation rate was 39.1%, and 71% (17/24) of TALEN pairs had 
mutation rates of >20% (Figure 34). However, for the 21 NK-TALEN pairs formed from 
the Training Set (designed without SAPTA), the average mutation rate was 3.5%, and 
only one TALEN pair had a mutation rate of >20%.  Further, we found that qualitative 
design guidelines proposed in two previous studies (1,2) are not sufficient in designing 
active NK-TALENs. As illustrated in Figure 34 and Supplementary Table S6 of reference 
(3), of the 35 NK-TALEN pairs that followed the three design guidelines suggested by 
Figure 33: T7E1 assay measuring the endogenous gene modification efficiency of 24 NK-TALEN 
pairs designed by SAPTA. 
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Reyon et al. (2) and the first two guidelines suggested by Streubel et al. (1), 21 pairs 








 Previously, five genes CDH1, HOXD13, FANCE, KIT and TGFBR2 were targeted 
by NN-TALENs without any success (2). The same five genes were targeted again by 
seven SAPTA-designed NK-TALEN pairs formed by TALENs in Test Set 2, resulted in 
gene modification rates of 1.6% - 69.2% (Figure 35 and Figure 33), further demonstrating 
the advantage of using SAPTA for TALEN designs. 
 
 
Figure 34: Activity distribution of SAPTA-designed NK-TALEN pairs targeting endogenous genes. 
The majority of NK-TALEN pairs designed by SAPTA have high activity targeting endogenous 
genomic loci (black columns), whereas unselected NK-TALENs built without design tools (white 
columns) and NK-TALENs that follow previous guidelines (1,2)  (grey columns) generally have low 








 Although SAPTA was established based on SSA measurements of NK-TALENs, 
we verified that it could also be used to identify target sites for highly active NN-
TALENs. We designed 14 pairs of NN-TALENs using SAPTA (Figure 36), including 9 
NN-TALEN pairs targeted to the same DNA sequences as the corresponding NK-
TALEN pairs formed from Test Set 2, and 5 NN-TALEN pairs targeted respectively to 
five genes AXIN2, EXT2, FANCA, FLT4 and HMGA2 (see more details below). We 
found that 71% (10/14) of SAPTA-designed NN-TALEN pairs had mutation rates of 
>20% (Figure 37), with an average mutation rate of 35.2%, similar to the SAPTA-
designed NK-TALEN pairs.  
 
 
Figure 35: Activity of SAPTA-designed NK-TALENs targeted to five previously attempted genes. 












Figure 36: T7E1 assay measuring the endogenous gene modification efficiency.  
(a) 14 pairs of NN-TALENs designed by SAPTA. (c) NN-TALENs obtained from a previous study(2) 
were tested using T7E1 assay in this study. Lane headings indicate the target genes and the left (L) and 
right (R) TALENs. “-” denotes samples treated with an empty TALEN backbone. Numbers below 






 As reported previously, NN-TALEN pairs conforming to existing guidelines (1,2) 
targeted five genes (AXIN2, EXT2, FANCA, FLT4, HMGA2) but showed mutation rates 
of <10% (2). We tested these NN-TALEN pairs (ordered from Addgene) in HEK293T 
cells (as with other TALENs we tested), and confirmed mutation rates of <10% (Figure 
36). Note that the EXT2-targeting TALEN pair contains a left TALEN with a negative 
SAPTA score, therefore is predicted to have low activity. Further, four of these TALEN 
pairs (AXIN2, FANCA, FLT4, and HMGA2) contained TALEN half-sites with >45% G, 
which is outside (higher than) the range of the G content considered in SAPTA. 
Specifically, for nucleotide G, the RVD NK has a low binding affinity, thus a large 
percentage of this RVD in a TALEN can substantially weaken the overall binding of 
TALEN to the DNA target (1); on the other hand, the RVD NN was shown to recognize 
A in addition to G (1), so more than 45% of the NN RVD will likely lower the specificity 
of the TALEN. Therefore, SAPTA does not consider target sequence with >45% G 
content.  We re-designed NN-TALEN pairs using SAPTA to target the same five genes 
<50 bp away from the previous targeted sites (2), and found that SAPTA-designed NN-
TALEN pairs resulted in mutation rates of 14.0% - 63.9%. Each pair is >7-fold more 









 There are two NK-TALEN pairs from Test Set 2 that showed high monomer SSA 
activities, but undetectable endogenous gene-modification rates: G-43/G-44 and G-47/G-
48 (Figure 33). Similar to the TALEN pair S-21/S-23 from the Training Set, these pairs 
contain large repeat arrays. The sum of the left and right repeats for each pair exceeds 45 
repeats, suggesting that the large sizes of TALEN dimers may prevent access to their 
target loci. Possibly due to the same reason, two NN-TALEN pairs (G-89/G-90 and G-
93/G-94) targeted to the same sites as G-43/G-44 and G-47/G-48, respectively, also failed 
to show any detectable gene-modification activity. There results suggest that caution 





Figure 38: Gene modification frequencies (% indels) of NN-TALEN pairs designed by SAPTA 
compared to NN-TALEN pairs from a previous study(2) targeted to the same gene regions.  
The T7E1 assay was used to measure the activities of these TALEN pairs in HEK293T cells.  Error 






Evaluation of existing design guidelines 
  For effective TALEN designs, the existing guidelines are inadequate, since too 
many potential TALEN target sites conform to the current guidelines (1,2), even within a 
short 100-bp gene segment.  Little guidance is given to identify the optimal target site for 
a gene of interest, especially with NK-TALENs. Reyon et al. and others (2,4,7,71) have 
shown that there is a large range of activities (and some with very low or non-detectible 
activity) among TALENs designed using the existing guidelines, even with NN-
 
Figure 39: Comparing frequencies of active NN-TALEN pairs tested by Reyon et al. (2) that meet or 
violate guidelines proposed by Streubel et al.(1).  
The 86 out of 96 pairs meet Streubel guidelines, and 10 out of 96 pairs violate the guidelines. Different 
mutation rates (% indels) are used as cut-offs for active TALEN pairs. Frequencies (%) of active 
TALEN pairs with mutation rates above these cut-offs are shown respectively. NS, not significant, as 
determined by Fisher’s exact test, with the hypothesis that meeting the guidelines increases TALEN 
activity. 
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TALENs.  For example, of the 35 NK-TALEN pairs we tested that followed the 
guidelines proposed by Streubel et al. (1), only 14 pairs (40%) had detectable gene-
modification activities (Figure 34). These guidelines did not seem to improve NN-
TALEN activity either. Among the 96 TALEN pairs targeting endogenous human genes 
tested by Reyon et al. (2), 86 TALEN pairs that followed the guidelines showed activity 
levels comparable to the 10 pairs violated the guidelines (Figure 39).  
 We further used SAPTA to examine the target sites of these 96 NN-TALEN pairs 
tested by Reyon et al. (2). Within the constraints of all variables, SAPTA identified 21 
TALEN pairs with composite scores above 30, which is our score threshold for active 
pairs. Only 2 of these 21 pairs have gene-modification rates below 10%, indicating a false 
positive rate of 9.5%. Without filtering by SAPTA, 28 out of 96 (29.2%) TALEN pairs 
have modification rates below 10%. The false positive rate of 29.2% for their original 
design is about three times higher compared to that using SAPTA. It should be noted that 
SAPTA parameters were optimized using NK-TALENs, thus the SAPTA scores may not 
correlate well with the activities of NN-TALENs. Nevertheless, our results suggest that 
SAPTA could be used to increase the chance of obtaining highly active NN-TALENs. 
Comparison between SAPTA and other TALEN design web tools 
  A few TALEN design tools have been published recently: TALE-NT 2.0 (78), 
Mojo Hand(79), and E-TALEN (80). While these tools can facilitate TALEN designs, we 
strongly believe that SAPTA is a much better design tool in helping researchers choose 
highly active TALEN designs from hundreds from hundreds perhaps even thousands of 
potential designs by providing an experiment-validated scoring/ranking system for 
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TALEN target sites. A brief evaluation of the previously published TALEN design tools 
in comparison to SAPTA is given below. 
TALE-NT 2.0 (78) 
 TALE-Nucleotide Targeter (NT) 2.0 tool was developed based on a minimal 
constraint (5’T) and recently proposed design guidelines (1).  These guidelines have not 
been experimentally validated, nor has the correlation between the proposed guidelines 
and higher TALEN activity been established. In fact, these guidelines do not seem to 
correlate with high TALEN activity (Figure 39). 
 In contrast, SAPTA provides TALEN designers with a ranked list of high-activity 
TALEN target sites. The TALE-NT tool does not have a ranking system for TALEN 
activity, although it provides scores for potential off-target sites for a given TALEN pair 
or TALE (78). TALE-NT tool scans a gene segment and identifies all target sites that 
meet the following three criteria specified by users without further discrimination / 
ranking: (1) a T or C precedes the 5’ end of each target half-site; (2) a spacer range; (3) a 
range for repeat array length.  As shown in the study by Reyon et al. et al. (2), TALENs 
that meet all these criteria have activities varying over a wide range, from 0% to 55.8% in 
a NHEJ-mediated mutagenesis assay. Designing TALENs solely based on these criteria 
may not lead to high cleavage activity. Since there is no sufficient guidance in selecting 
target sites, the chances for picking up high-activity TALEN are equal to randomly 
choosing TALEN target sites. Unlike TALEN-NT, SAPTA outputs a ranked list of 
TALEN target sites predicted to give high activity, which has been experimentally 
validated. We have shown that TALENs designed by SAPTA have significantly higher 
activity compared to those designed by other methods.  
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 TALE-NT typically provides hundreds of potential target sites that meet the 
design criteria without further discrimination.  In contrast, SAPTA provides a ranked list 
of target sites with SAPTA scores, allowing researchers to choose the top-ranked 
TALENs for testing. For comparison, we used TALEN-NT 2.0 to search the 350-bp HBB 
gene fragment containing the sickle cell mutation site. We used the default criteria based 
on Miller et al. architecture, which specified spacer ranges from 15-20 bases and RVDs 
ranging from 15-20. TALEN-NT 2.0 output 3,612 un-ranked target sites for this region, 
but there is no guidance for deciding which TALENs to construct and test. There is the 
option to hide redundant TALENs, where TALEN-NT selected the pair with the shortest 
average length of repeat arrays and spacer and provided 240 unranked TALEN pairs. 
However, the hypothesis that shorter spacer and length of repeat arrays are better has not 
been experimentally validated.  
 Of the 3,612 potential target sites identified by TALEN-NT 2.0, we tested NK-
TALEN pairs designed for eight target sites. Six out of the eight pairs showed no 
detectable gene modification rate (Table 3). The six pairs with no activity were ranked 
low by SAPTA, all with composite scores lower than 30 (the cut-off score for TALEN 
pairs considered to be active). Therefore, the ranking provided by SAPTA is a dramatic 
improvement over TALEN-NT. SAPTA also allows researchers to compare SAPTA 
scores and the position of the target sites relative to a mutation site to better evaluate the 





Table 3: SAPTA ranking results for eight target sites provided by a search using TALEN-NT 2.0 (78). 
Cellular activity measured as % indels using the T7E1 assay is shown for TALEN target sites tested in this 
study that were also found in the 3612 target sites in the TALEN-NT 2.0 output for this gene segment.  The 
SAPTA composite score is shown for each pair and is used to select high scoring sites for TALEN 
targeting and to screen against using sub-optimal sites (composite score < 30), such as the third through 
eighth rows below.  The TALEN pairs with SAPTA composite scores above 30 had detectiable endogenous 
gene targeting, whereas those with lower scores, did not have detectable activity. 
 
 
Gene L-TALEN L-score R-TALEN R-score Composite scorea %indels±s.e.m.  
HBB S-116 30.5 S-120 19.5 44.7 43.4±1.4 
HBB S-02 19.9 S-12 4.8 31.6 7.6±0.7 
HBB S-133 8.0 S-134 5.4 25.7 0 
HBB S-127 9.7 S-128 1.9 25.5 0 
HBB S-115 3.5 S-119 8.6 24.2 0 
HBB S-131 11.1 S-132 1.4 23.0 0 
HBB S-129  2.6 S-130 7.3 22.2 0 
HBB S-114 17.6 S-117 -2.1      N/Ab 0  
 
a , where LS is the L-score (left TALEN score), and RS is 
the R-score (right TALEN score).  




Mojo Hand (79) 
 Mojo Hand is a basic tool that applies a loose filter for possible TALEN target 
sites in a given gene segment. Besides user-defined ranges of spacer length and repeat 
array length, the only constraint applied is the requirement for a 5’T before each target 
site. As mentioned above, a loose filter results in hundreds of unranked potential TALEN 
target sites, making it difficult for users to identify the best TALENs to construct. 
 To illustrate, a 350-bp DNA sequence was given as input into Mojo Hand with 
15-16 bp spacer lengths and 15-17 TALEN repeat array lengths, and Mojo Hand gave 
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325 possible target sites as output. Without further discrimination, users of this website 
would have no guidance on which TALEN pairs they should construct among the 325 
possible choices. The Mojo Hand publication validated one single pair of TALENs, but it 
was not apparent how this pair was chosen (79).  
E-TALEN (80) 
 E-TALEN is a new web-based tool that aims to help researchers with TALEN 
designs. It was difficult to evaluate E-TALEN, since it does not always provide 
functional output.  For example, when a segment of the HBB gene (350 bp) was used as 
input with the default settings of the E-TALEN website to design TALEN pairs, E-
TALEN gave an output of four TALEN pairs that have their target sites only differ by 
one or two bases. Further, alignment of these TALEN target sites against the input DNA 
sequence revealed that the orientation of these TALEN pairs was incorrect: Functional 
TALENs bind to DNA in the 5’ to 3’ orientation (N to C terminal of TALEN). However, 
the four TALEN pairs designed by E-TALEN have the opposite orientation, which 
resembles the binding orientation of zinc finger nucleases.  When the default setting in E-
TALEN was changed to allow for up to 50 pairs of TALENs in the output, most of the 
TALEN pairs designed by E-TALEN targeted the same position; the target sites only 
differ by a few bases. Again, all of the 50 TALEN pairs are in the ZFN-like (3’-to-5’) 
orientation, which is incorrect according to published experimental results.  
 To further test E-TALEN, a 350-bp gene segment from the myocilin gene was 
used as input with the default setting changed to allow for up to 50 pairs of TALENs in 
the output.  The TALEN pairs given by E-TALEN target the same position; the target 
sites only differ by a few bases. Of these 50 TALEN pairs, 27 TALEN pairs have the 
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wrong, ZFN-like orientation (3’-to-5’); only 23 pairs have the correct, 5’-to-3’ 
orientation. 
 In summary, it appears that E-TALEN (Version 2.4) outputs TALEN target sites 
with both 3’-to-5’ and 5’-to-3’ orientations, and the range of different TALEN target sites 
is very limited.  
Frequency of highly active TALENs with and without using SAPTA 
 The “success rates” claimed by previous studies categorized all detectable 
activities, whether 1% or 50% mutation rates measured by T7E1 assays, as being success 
(2,4,7). In contrast, SAPTA aims to increase the levels of activities, in addition to 
increasing the fraction of TALENs that have detectable activity. We compared the 
frequencies of “highly active” TALEN pairs designed using SAPTA to those reported in 
previous studies (2,4,7). Due to possible differences in experimental conditions across 
various studies, we categorized “highly active TALENs” by gauging TALEN activities 
within each study using the highest TALEN activity measured in the same study. 
Specifically, the “maximum mutation rate” was defined as the highest mutation rate 
observed in each individual study. The cut-offs for “high activity” were set at a range of 
activities depending on different maximum mutation rates, ranging from 20% to 80% of 
each maximum mutation rate (Figure 40). The number of highly active TALEN pairs 
with activities higher than each cut-off was counted. Using this sliding cut-off, we 
showed that frequencies of highly active TALEN pairs designed by SAPTA were at least 
twice the frequencies in other studies at higher cut-offs (40% - 80% of maximum 
mutation rate) (Figure 40). Therefore, SAPTA-designed TALENs showed a significant 
improvement in achieving high activity. Having TALEN pairs with high activity levels 
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(for example, ~40%) compared to those simply meet the relatively low bar of being 










Figure 40: Frequencies of highly active TALEN pairs with and without SAPTA.  
“Highly active” is defined by a range of different cut-offs (x-axis) from >20% to >80% of the maximal 
TALEN-mediated mutation rates (% indels) observed in each study. Fractions of maximal % indels 
were used as cut-offs since the results of T7E1 assays may vary among different studies. SAPTA-
designed NK- and NN-TALENs are shown comparing to TALENs from previous studies by Reyon et 
al. (2), Schmid-Burgk et al. (4), and Kim et al. (7). Asterisks indicate two-sided P-values associated 
with SAPTA-designed TALENs compared to NN-TALENs by Reyon et al.. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001 as determined by Fisher’s exact test. 
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4.3  Discussion 
 SAPTA is the first quantitative and experimentally-validated design tool for 
selecting TALEN target sites with high cleavage activity. This represents a significant 
advance over existing TALEN design tools that often output hundreds to thousands of 
unranked potential target sites (Table 4 and Table 3). Although the target sites selected by 
E-TALEN are ranked (81), the ranking is based on the guidelines by Cermak et al. (23), 
which were shown by Reyon et al. (2) to lack significant correlation with TALEN 
activity. In contrast, SAPTA has quantitatively incorporated a wide range of TALEN 
design guidelines (1,2,23) and provides a ranked-list of potential target sites, allowing 













Correct TALEN design √ √ √ ×
a 
Scoring system √ × ×  √
 b 
Experiment validation √ ×   √
 c × 
Number of hits for a 350-
bp HBB sequence 32 3,612 325 1,902 
 
a Some TALEN designs have the wrong, 3' to 5' binding direction. 
b The scoring in E-TALEN (81) is based on the guidelines by Cermak et al. (23), which were shown by 
Reyon et al. (2) to lack significant correlation with TALEN activity. 





 We demonstrated that SAPTA-designed NK-TALENs improved the average 
monomer SSA activity from 8.6% to 27.2%, and SAPTA-designed NK- and NN-TALEN 
pairs have significantly higher endogenous gene-modification rates compared to those 
designed without SAPTA (2,4,7) (Figure 40), with 71% of SAPTA-designed NK- or NN-
TALEN pairs showing gene-modification rates of >20%. Compared with the reported 
activity distributions of NK- (4) and NN-TALEN (2,7) pairs studied previously, SAPTA-
designed NK- and NN-TALEN pairs showed better performance, since the majority of 
the TALEN pairs gave high mutation rates (Figure 34), whereas the activity distribution 
of previously tested NK- and NN-TALEN pairs peaks at much lower (1-20%) mutation 
rates (Figure 34 and Figure 41). Our results indicate that SAPTA-designed TALEN pairs 
with composite scores >30 generally resulted in high endogenous gene-modification rates 
















Figure 41: Distribution of TALEN-pair activities in previous publications.  
(a) NK-TALEN pairs tested by Schmid-Burgk et al.(4). (b) NN-TALEN tested by Reyon et al.(2). (c) 
NN-TALEN pairs tested by Kim et al.(7). 
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 Further, our analysis suggests that SAPTA on average identifies high-scoring 
target sites within the first 24 bp in a search through the coding sequences of 48 human 
genes (Figure 42), thus allowing versatile gene editing using TALENs. To test the 
frequency of high-scoring TALENs in regular human genes, the first 500 bp of the 
mRNA sequence of the open reading frames of the first 48 genes listed in Reyon et al. (2) 
was obtained from the UCSC Genome Browser. The entire ORF was analyzed if the ORF 
was shorter than 500 bp. Each sequence was analyised using the SAPTA online targeter 
and the average distances from the start codon to the closest site scoring above 30, 35, 40, 
and 45 were noted. The average of these distances for scores 30 and higher was 24 bp 
with a standard deviation of 31 bp. While this is not as frequent as guidelines published 
by Reyon et al.(2) (every 1/3 bp), it is comparable to the frequency of sites using the 
guidelines published by Cermak et al. (23) (every 35 bp). We were able to find seven 
pairs of TALENs with scores above 40 in the 200-bp β-globin region centered by the 
sickle cell mutation. Some target sites in our search were excluded as restrictive 
constraints were used that limited the ranges of variables to within the values of the 
training data set. Restrictive constrains may be used as activities of TALENs outside 
these constraints may not be well predicted by SAPTA, although they can still have high 










 Our results suggest that the activity of TALENs depends on numerous inter-
related variables, and no single variable is able to fully explain the variation in activity 
levels. Therefore, quantitative integration of various design criteria is likely required for 
successful TALEN designs. For example, the target site for TALEN S-91 contains 43% C 
(recognized by the strong RVD HD), but its SSA activity was only 1.7% (3). We believe 
that multiple design variables act synergistically to affect TALEN activity, and attempted 











Figure 43: Two pairs of ERCC5-directed TALENs in the training set effectively cleaved their plasmid 
targets, but do not result in endogenous gene targeting.  
(a) T7E1 assay at endogenous genes. (b) Comparison between percentages of indels at endogenous 
gene target sites (quantified from a) and composite SAPTA scores. Error bars, s.e.m. (n=3) (c) Hetero-
dimeric SSA activity for two ERCC5-targeting TALEN pairs is comparable to the active β-globin 
(HBB) pair. The assay performed, as above, using a hetero-dimeric target plasmid co-transfected with 
both TALEN monomers. “-” represents a negative control; G-ZFN-L and G-ZFN-R represent the 
GFP-ZFN pair as in Supplementary Figure S3. Arrow indicates the position of SSA-repaired products. 
(d) Levels of hetero-dimer %SSA activity (quantified from c) compared with composite SAPTA 
scores. Error bars, s.e.m. (n=3). (e) T7E1 assay at plasmid targets showed similar activities of HBB-
targeting and ERCC5-targeting pairs. The larger band as shown in b was gel-isolated and used to 
perform the T7E1 assay, detecting the NHEJ-induced mutagenesis at the plasmid target. (f) 
Comparison between percentages of indels at plasmid target sites (quantified from e) and composite 
SAPTA scores. Error bars, s.e.m. (n=2). 
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 The SAPTA algorithm was trained using cleavage activity of TALEN monomers 
on plasmid substrates to avoid the complications induced by genomic context and other 
cellular factors, and minimize the variability associated with testing TALENs in pairs. 
However, the nuclease-induced endogenous gene modification efficiency is determined 
by the intrinsic activities of TALENs and the genomic context, including epigenetic 
factors, competing transcription factor binding sites and secondary structures. TALENs 
with similar activity levels in cleaving plasmid targets may have very different levels of 
activity when targeting different endogenous genes, as shown in Figure 43. Therefore, 
quantitative prediction of the rate of endogenous gene modification is challenging, and 
the SAPTA composite score for TALEN pairs calculated by combining the monomer 
TALEN sores is a semi-quantitative estimate of TALEN activity. However, TALENs 
targeting different sites within a short stretch of gene segment are likely to be influenced 
by similar genomic factors. Therefore, although the effect of TALENs in cleaving 
endogenous genes might not be accurately modeled by SAPTA due to genomic factors, 
SAPTA has the potential to rank different (nearby) target sites correctly and help 
researchers locate the optimal sites within a short gene segment.  
 SAPTA is based on the sum of scores corresponding to different design 
considerations. Therefore, it is flexible and will be able to incorporate more design 
variables into the function, as more information about factors affecting TALEN activity 
becomes available. The variables and parameters in the SAPTA algorithm can also be 
adaptively re-trained using new training sets of TALENs with different architectures or 
using alternate RVDs, such as NH. We anticipate that SAPTA will become a useful and 
flexible tool for designing highly active TALENs for genome editing applications. 
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4.4  Materials and methods 
Assembly of TALENs 
 All TALENs were assembled using a modified two-step Golden Gate cloning 
method (23) to link DNA-binding repeats (plasmids kindly provided by Daniel F. Voytas, 
University of Minnesota) containing RVDs HD, NI, NG, and NK to recognize C, A, T, 
and G, respectively, to a wild-type FokI nuclease domain (3). Additional TALENs were 
assembled using the NN RVD to recognize G. The TALEN backbone vector was 
constructed by incorporating a Kozak sequence, a triple FLAG epitope tag, and a 
previously described TALEN framework (24) into the pcDNA3.1(-) vector using NheI 
and AflII restriction sites (3).  
 After the first Golden Gate ligation step, intermediate repeat arrays (pFUS) with 
≤10 repeats were fully sequenced to confirm correct assembly. In the second Golden Gate 
step, two or three of these repeat arrays were ligated into the TALEN backbone vector 
using BsmBI restriction sites to replace a lacZ gene stuffer fragment for blue/white 
screening.  The clones were then sequenced using flanking primers to confirm the outside 
cloning sites and arrays, though the reads do not allow re-sequencing of the middle 
arrays.  The final TALEN plasmids were also validated by digestion with SacII and 
BamHI to confirm the total size, and digestion with BspEI, which cuts only in HD 
repeats.  
 All sequencing primers are described in the Golden Gate TAL Assembly protocol 
available online at http://www.addgene.org. Complete sequences of all TALEN plasmids 




Assembly of single strand annealing (SSA) reporter plasmids 
 The SSA reporter plasmid backbone contains an EGFP gene, interrupted after 327 
bp with a stop codon, the target site for a pair of GFP-targeted ZFNs (63), an AscI, and 
an SbfI cloning site (3). The downstream portion of the EGFP gene includes a 42-bp 
region repeating the sequence of the EGFP gene before the stop codon. SSA reporters 
were constructed using oligonucleotide pairs containing the left target site, the spacer, 
and the right target site ligated into the vector’s AscI and SbfI sites (Figure 12). 
SSA activity assay 
 Human embryonic kidney 293T (HEK293T) cells (ATCC) were cultured in 
Dulbecco’s Modified Eagle Medium (Sigma), supplemented with 10% FBS and 2 mM L-
glutamine. Cells were seeded 80,000 per well of a 24-well plate. After 4 h, cells were 
transfected with 200 ng of the TALEN plasmid (or 100 ng of each TALEN for hetero-
dimeric pairs) and 10 ng of the corresponding SSA reporter plasmid using calcium 
phosphate transfection. Three control transfections were included: 1) 200 ng of an empty 
TALEN backbone and 10 ng of an SSA reporter plasmid, 2) 200 ng of an empty TALEN 
backbone and 10 ng of a pEGFP plasmid, and 3) 100 ng of each GFP-ZFN and 10 ng of 
an SSA reporter plasmid. Cells were harvested 48 h after transfection. The percentages of 
pEGFP-transfected samples expressing GFP were determined using an Accuri C6 flow 
cytometer, as an indication of transfection efficiency. Cells were lysed using 
QuickExtract DNA extraction solution (Epicentre) as described(58). Sample were PCR 
amplified for 35 cycles (95 °C, 30 s; 60 °C, 30 s; 72 °C, 60 s) in a 50 µl reaction that 
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contains 2 µl of the cell lysate, 2.5 µl of each 10 µM target region amplification primer 
(SSA-Cell-F4, 5’-TCGTGACCACCCTGACCTACGG; SSA-Cell-R4, 5’-
TGCCGTCCTCGATGTTGTGGCG), and 25 µl of GoTaq green master mix (Promega). 
PCR reactions were then separated on 2% agarose gels and the percentages of SSA-
repaired products relative to the total PCR products were quantified using ImageJ. 
Standard curve for SSA assay 
 To generate the standard curve, EGFP plasmid (pEGFP), with a sequence 
identical to the SSA-repaired target plasmid, and a target plasmid were mixed at different 
ratios. HEK293T cells were transfected with the mixtures and an empty TALEN 
backbone, the genomic DNA harvested and the SSA assay performed, as above. The 
results from three transfections were averaged and plotted comparing the percentage of 
the EGFP plasmid versus the percentage of the smaller band (345 bp).  Figure 24 shows 
that the near-linear relationship is valid up to ~50% of EGFP plasmid in the mixture. 
SAPTA algorithm 
 The SAPTA algorithm is a fitted model containing an optimized set of dummy 
variables and continuous variables. Dummy variables were used to describe base 
identities of the first five and the last five nucleotides in the monomer target sequence, 
whereas cubic functions were used to characterize the effect of changes in other 
variables, including the length of the target sequence, the overall percentages of each 
nucleotide in the target sequence, percentages of each nucleotide in the first five or the 
last five nucleotides, and the maximum numbers of consecutive A’s and G’s (1,50) 
(Supplementary Table S1 of reference (3)). Cubic functions were chosen because third-
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degree polynomials have the flexibility to approximate various curves, including linear, 
parabola, exponential, and asymmetric concave curves. 
 A SAPTA score predicts the activity of a TALEN monomer. As shown in 
Equation 1, the SAPTA score S of each monomer target sequence is calculated as the sum 
of seven terms: 
 S = SPOS + SN + SPER + SPER,F5+ SPER,L5+ SCONS+ C0   (Eqn. 1) 
where C0 is a constant. 
 SPOS = F(d1)+F(d2)+F(d3)+F(d4)+F(d5)+F(dN-4)+F(dN-3)+F(dN-2)+F(dN-1)+F(dN)  
          (Eqn. 2) 
SPOS represents the effects of each nucleotide at the first five and last five positions of the 
target sequence (e.g. the impact of having a C as the first nucleotide in the target 
sequence), where  
 F(di) = βi,A*di,A+βi,C*di,C+βi,G*di,G+βi,T*di,T    (Eqn. 3) 
The dummy variable di,x in Equation 2 is either 1 (if the nucleotide at the position i is x) 
or 0 (otherwise). Positions are numbered starting from the first nucleotide after the 5’-T. 
N in Equation 2 denotes the total number of nucleotides in the sequence. For example, dN 
corresponds to the last nucleotide at the 3’ end of the sequence. Parameters (βi) associated 
with the variables (di) are optimized as described below, and can be found in 
Supplementary Table S1 of reference (3).  
 SN = Q(N)        (Eqn. 4) 
SN represents the effect of the length of target sequence (N); 
 SPER = Q(%A)+Q(%C)+Q(%G)+Q(%T)    (Eqn. 5) 
SPER represents the effect of the overall base composition (percentages of A, C, G, T); 
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 SPER,F5 = Q(%AF5)+Q(%CF5)+Q(%GF5)+Q(%TF5)   (Eqn. 6) 
SPER,F5 represents the effect of the base composition of the first five nucleotides (%AF5, 
%CF5, %GF5, and %TF5); 
 SPER,L5 = Q(%AL5)+Q(%CL5)+Q(%GL5)+Q(%TL5)   (Eqn. 7) 
SPER,L5 represents the effect of the base composition of the last five nucleotides (%AL5, 
%CL5, %GL5, and %TL5); 
 SCONS = Q(ACONS)+Q(GCONS)      (Eqn. 8) 
SCONS represents the effect of the maximum numbers of consecutive A’s (ACONS) and 
consecutive G’s (GCONS).  In equations (4-8), Q(x) is a cubic function defined as  
 Q(x)  ax
3  bx2  cx d   
where the values of a, b, c are listed in Supplementary Table S1 of reference (3). The 
constant terms d from each cubic function were combined and solved as the constant C0 
in Equation 1.  
 In the original functions that form the SAPTA algorithm, there are a total of 55 
variables and 86 parameters. Specifically, the 55 variables include 4 x 10 (type of 
nucleotide x number of positions) dummy variables di,x which have values of either 1 or 
0, and 15 other variables (length of target, %A, %C, %G, %T, etc.) each associated with 
a cubic function. The 86 parameters include 40 parameters each associated with one 
dummy variable, 3 parameters for each cubic function (3 x15=45), and one constant the 
represents all the constants in the cubic functions. 
 To fully establish the algorithm in SAPTA showed above, 130 NK-TALENs were 
individually tested for their monomer SSA activity in cultured cells. The experimental 
results of the Training Set were used for linear regression to determine the parameters in 
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the SAPTA algorithm using the statistical software R. Since the number of explanatory 
variables is relatively large compared to the number of TALENs in the Training Set, we 
follow the standard statistical approach to use the step function in R to perform a model 
selection that eliminates non-essential variables whose parameters were set to zeros, as 
shown in Supplementary Table S1 of reference (3). The final functions in the SAPTA 
algorithm contain 30 variables and 43 parameters. 
 The fitted SAPTA functions were used to determine the overall optimal base 
composition shown in Table 2. Specifically, the score contribution of the overall base 
composition in the first 5 nucleotides was calculated using the following SAPTA function 
(non-essential variables were removed as described above): 
 Score contribution of the base composition = 
1.66E-04×(%A)3+ (-1.05E-00)×(%A)+ 1.36E-03×(%C)3+ (-1.42E-01) ×(%C)2  
+ 4.26E+00×(%C) +1.18E-03×(%G)3 +(-6.49E-02) ×(%G)2 +3.01E-04×(%T)3  
+(-2.91E-02) ×(%T)2         (Eqn. 9) 
The ranges of %A, %C, %G, and %T in the Training Set are 0-56.3%, 14.3-53.3%, 0-
45.0%, and 4.2-55.6%, respectively. Thus the equation above was solved using these 
constraints to find the maximum score contribution. The optimal solutions were found as 
0% A, 53% C, 10% G and 37% T. 
Composite SSA activity and score 
 Composite SSA activity was calculated to estimate TALEN pair activity at 
endogenous genes. The following equation combines square roots of monomer activities 
measured by the SSA assay, allowing TALEN pairs with more balanced (closer) left and 
right TALEN activities to obtain a higher calculated composite activity. 
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     (Eqn. 10) 
The numerical factors in Equation 10 were chosen so that the composite SSA activity is 
~30 when both the left and right TALEN SSA activities are ~10%.  Similar to the 
composite SSA activity, the composite score of a TALEN pair is calculated with the 
following equation to allow pairs with more balanced left and right TALEN scores to be 
ranked higher, since TALEN pairs with more balanced left and right monomer activities 
displayed better performance in pairs (Table 5). 
  (Eqn. 11) 




Table 5: Comparison of TALEN pairs with balanced and unbalanced monomer activities. 
To determine if TALEN pairs with balanced monomer activities outperform TALEN pairs with drastically 
different left (L) and right (R) TALEN monomer activities, pair activities were measured using hetero-
dimeric target plasmids in an SSA assay. The use of target plasmid minimizes the effect of genomic 
context. Specifically, TALEN pairs with a similar sum of activities but different left and right monomer 
activities are compared (e.g. 77+1=78 vs. 53+25=78). Three comparisons with different spacer lengths are 
shown. 
 
L R Spacer L %SSA R %SSA Sum %SSA Hetero-dimeric %SSA 
J-11 J-15 18 54  1 55  6 
S-116 S-120 18 30 24 54 18 
S-16 S-22 17 31  4 35  6 
G-02 J-02 17 18 17 35 19 
J-16 J-15 15 77  1 78  3 






SAPTA web interface and source code  
 The Web interface of the SAPTA online search tool can be found at 
http://baolab.bme.gatech.edu/Research/BioinformaticTools/TAL_targeter.html. The 
SAPTA web page allows for entering gene segments and basic parameters such as search 
type, maximum and minimum spacer lengths, and maximum and minimum TAL array 
lengths. The SAPTA output table contains the starting position of the left TALEN target 
half-sites, the left and right TALEN sequences, the sizes of the left TALEN, right 
TALEN and spacer, and the composite score of the TALEN pair. More details on the 
SAPTA web interface are provided on the website. 
 The source code for the online SAPTA search tool can be found at: 
http://baolab.bme.gatech.edu/Research/BioinformaticTools/ScoreTALEBindingSites2.js.  
T7 endonuclease I (T7E1) mutation detection assay for measuring endogenous gene 
modification 
 The gene modification efficiency of hetero-dimeric TALEN pairs was quantified 
based on the level of imperfect repair of double-stranded breaks by NHEJ.  HEK293T 
cells were seeded 40,000 per well of a 24-well plate. After 24 hrs, cells were transfected 
with 500 ng of each nuclease (TALEN or ZFN) plasmid and 10 ng of pEGFP plasmid 
using 3.4 µl FuGene HD (Promega), following manufacturer’s instructions.  Cells were 
harvested 72 h after transfection and analyzed with an Accuri C6 flow cytometer to 
quantify GFP fluorescence, as a measurement of transfection efficiency. Cell pellets were 
then collected and genomic DNA isolated using QuickExtract DNA extraction solution 
(Epicentre), as described in (58). T7E1 assays were performed, as described 
previously(2) and the digestions separated on 2% agarose gels. The cleavage bands were 
 98
quantified using ImageJ. The percentage of gene modification = 100x (1 – (1-fraction 
cleaved)0.5), as described in (58). Primers used for this assay are listed in Supplementary 
Table S3 of reference (3). All PCR reactions were performed using AccuPrime Taq DNA 
Polymerase High Fidelity (Life Technologies) following manufacturer’s instructions for 
35 cycles (94 °C, 30 s; 60 °C, 30 s; 68 °C, 60 s) in a 50 µl reaction containing 2 µl of the 
cell lysate, 2.5 µl of each 10 µM target region amplification primer, and 5% DMSO. The 
PCR reactions for the FANCE locus gave non-specific bands under standard conditions 
and were amplified after addition of 1 M betaine.   
Single molecule real time (SMRT) sequencing of NHEJ induced mutations 
 The same PCR products used for T7E1 assays were pooled for SMRT sequencing 
following the manufacturer’s instructions (Pacific Biosciences). NHEJ mutations were 
detected and analyzed using algorithms recently developed (73) and compared to mock 
transfected cells. 
Fisher’s exact test 
 Fisher’s exact test was used to determine the association of using SAPTA with 
achieving larger percentages of “highly active” TALEN monomers / pairs. For TALEN 
monomers, a 10% SSA activity was used as a cut-off for high activity. Therefore, 
TALENs with SSA activities >10% were considered to have “high SSA activity”, and 
those with SSA activities ≤10% to have “low SSA activity”. A two-tailed P-value was 
calculated using Fisher’s exact test to compare the distribution of high and low SSA 
activities in the Test Set 2 and the Training Set. To evaluate the performance of TALEN 
pairs tested in this work, we took into account the variability of T7E1 assay in previously 
studies (2,4,7). In each case, we used fractions of the maximum indel percentage 
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observed in this particular study as the cut-off values. Furthermore, to avoid arbitrarily 
choosing cut-off, we applied sliding cut-offs at 20%, 30%, 40%, 50%, 60%, 70%, and 
80% of the maximum indel percentage. TALENs with indel percentages higher than a 
cut-off value were considered to be “highly active”. Two-tailed P-values were calculated 




CHAPTER 5: CHARACTERIZATION OF CRISPR/CAS9 OFF-
TARGET EFFECT AT GENOMIC SITES WITH INSERTIONS OR 
DELETIONS 
 CRISPR/Cas9 systems are a versatile tool for genome editing due to the highly 
efficient targeting of DNA sequences complementary to their RNA guide strands. 
However, it has been shown that RNA-guided Cas9 nuclease cleaves genomic DNA 
sequences containing mismatches to the guide strand. A better understanding of the 
CRISPR/Cas9 specificity is needed to minimize off-target cleavage in large mammalian 
genomes. Here we show that genomic sites could be cleaved by CRISPR/Cas9 systems 
when DNA sequences contain insertions (‘DNA bulge’) or deletions (‘RNA bulge’) 
compared to the RNA guide strand, and Cas9 nickases used for paired nicking can also 
tolerate bulges in one of the guide strands. Variants of single-guide RNAs (sgRNAs) for 
four endogenous loci were used as model systems, and their cleavage activities were 
quantified at different positions with 1-bp to 5-bp bulges. We further investigated 114 
putative genomic off-target loci of 27 different sgRNAs and confirmed 15 off-target sites, 
each harboring a single-base bulge and one to three mismatches to the guide strand. Our 
results strongly indicate the need to perform comprehensive off-target analysis related to 
DNA and sgRNA bulges in addition to base mismatches, and suggest specific guidelines 
for reducing potential off-target cleavage.  
5.1  Introduction 
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 Advances with engineered nucleases allow high-efficiency, targeted gene editing 
in numerous organisms, primary cells and cell lines.  Gene editing was used to create 
user-defined cells, model animals and gene-modified stem cells with novel characteristics 
that can be used for gene functional studies disease modeling and therapeutic 
applications. Clustered regularly interspaced short palindromic repeats (CRISPR) and 
CRISPR-associated (Cas) proteins constitute a bacterial defense system that cleaves 
invading foreign nucleic acids (33-40). Chimeric single-guided RNAs (sgRNAs) based 
on CRISPR (41) have been engineered to direct the Cas9 nuclease to cleave 
complementary genomic sequences when followed by a 5’-NGG protospacer-adjacent 
motif (PAM) in eukaryotic cells (17,42,43). Since gene targeting by CRISPR/Cas9 is 
directed by base pairing, such that only the short 20-nt sequence of the sgRNA needs to 
be changed for different target sites, CRISPR/Cas systems enable simultaneous targeting 
of multiple DNA sequences and robust gene modification (17,18,41,42,44-48). 
  Endogenous DNA sequences followed by a PAM sequence can be targeted for 
cleavage by designing a ~19-nt sequence of the sgRNA complementary to the target. 
However, other sequences in the genome may also be cleaved non-specifically, and such 
off-target cleavage by CRISPR/Cas systems remains a major concern. Generally 
speaking, there is a partial match between the on- and off-target sites, and the differences 
between the on- and off-target sequences can be grouped into three cases: (a) same length 
but with base mismatches; (b) off-target site has one or more bases missing (‘deletions’); 
(c) off-target site has one or more extra bases (‘insertions’). Recent studies have shown 
that CRISPR/Cas9 systems non-specifically cleave genomic DNA sequences containing 
base-pair mismatches (case a) generating off-target mutations in mammalian cells with 
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considerable frequencies (5,51-55). Mismatches in the PAM sequence are less tolerated, 
although Cas9 also recognizes an alternative NAG PAM with low frequency (52,54,82). 
In addition, Cas9 off-target cleavage at a similar gene sequences with a base-pair 
mismatch may lead to gross chromosomal deletions with high frequencies, as 
demonstrated by the deletion of the 7-kb sequence between two cleavage sites in HBB 
and HBD respectively (5). These results indicate that, although Cas9 specificity extends 
past the 7-12 bp seed sequence (52,53), off-target effects may limit the applications of 
Cas9-mediated gene modification, especially in large mammalian genomes that contain 
multiple DNA sequences differing by only a few mismatches. A recent report revealed 
that 99.96% of the sites previously assumed to be unique Cas9 targets in human exons 
may have potential off-target sites containing a functional (NAG or NGG) PAM and one 
single-base mismatch compared with the on-target site (54).  
 In this work we investigated the above-mentioned cases (b) and (c) of potential 
CRISPR/Cas9 off-target cleavage in human cells by systematically varying sgRNAs at 
different positions throughout the guide sequence to mimic insertions or deletions 
between off-target sequences and RNA guide strand. To avoid confusion, for single-base 
insertions, we use a ‘DNA bulge’ to represent the extra, unpaired base in the DNA 
sequence compared with the guide sequence. Similarly, for single-base deletions, we use 
a ‘RNA bulge’ to represent the extra, unpaired base in the guide sequence compared with 
the DNA sequence (Figure 44). Therefore, adding a base into the guide RNA would 
result in an RNA bulge, while removing a base in the guide strand can be used to model a 
DNA bulge. The cleavage activity of RNA-guided Cas9 at endogenous loci in HEK293T 
cells transfected with plasmids encoding Cas9 and sgRNA variants was quantified as the 
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NHEJ-induced mutation rates. We found that off-target cleavage resulted from the 
sgRNA variants occurred with DNA bulge or sgRNA bulge at multiple positions in the 
guide strands, sometimes at levels comparable to or even higher than those of original 
sgRNAs.  We further examined the Cas9-mediated mutagenesis at 80 potential off-target 
loci in the human genome carrying single-base DNA bulges or sgRNA bulges together 
with a range of base mismatches, and confirmed two off-target sites with mutation 
frequencies up to 45.5%. Our results clearly indicate the need to search for genomic sites 
with base-pair mismatches, insertions and deletions compared with the guide RNA 
sequence in analyzing CRISPR/Cas9 off-target activity and in designing RNA guide 





Figure 44: Schematic of CRISPR/Cas9 off-target sites with (a) 1-bp insertion (DNA bulge) or (b) 1-bp 
deletion (RNA bulge). 
The 20-nt guide sequence (orange line) in the sgRNA is shown with genomic target sequence 
(protospacer) containing single-base DNA bulge (red asterisk) or single-base sgRNA bulge (red Δ). 
The zoom-in sequences of protospacer and PAM are shown above the sgRNA guide sequence. 





5.2  Results 
Cas9 cleavage with sgRNA variants containing single-base DNA bulges 
 To determine if CRISPR/Cas9 systems tolerate genomic target sites containing 
single-base DNA bulges (Figure 44a), we used the sgRNA-DNA interfaces of two 
sgRNAs, R-01 and R-30, targeting the HBB and CCR5 genes, respectively as a model 
system (5). Systematically removing single nucleotides at all possible positions 
throughout the original 19-nt guide sequences of R-01 and R-30 resulted in single-base 
DNA bulges at their original HBB and CCR5 target sites that model single-base insertion 
at potential off-target sites in the genome (Figure 45).  
 Cleavage of the genomic DNA in HEK293T cells was quantified using the T7E1 
mutation detection assay. For both groups of sgRNA variants (generated from R-01 and 
R-30 respectively), single-base DNA bulges at certain positions in the DNA sequences 
were well tolerated (e.g., still had Cas9 induced cleavage), though variants of R-30 had 









 For both groups, it was clear that Cas9 tolerated DNA bulges in target sites in 
three regions: 7 bases from PAM, the 5’-end (PAM-distal), and the 3’-end (PAM-
proximal). Specifically, -1nt variants of R-01 induced Cas9 cleavage activity when a 
single-base DNA bulge is present at positions 1 or 2, 6 or 7, 18, and 19 of the target DNA 
Figure 45: Activity of sgRNA variants targeted to genomic loci containing single-base DNA bulges. 
A single nucleotide was deleted from the original sgRNA at all possible positions (red dashes) 
throughout the guide sequence for (a) sgRNA R-01 targeting HBB or (b) sgRNA R-30 targeting CCR5.  
Cleavage activity for the corresponding sgRNA variants measured by T7E1 assay in HEK293T cells at 
(c) the HBB site or (d) CCR5 site for the sgRNA variants in (a) and (b). Sequence of the original 
sgRNA is in the top row of the grid. Positions of the deleted nucleotides are highlighted for A (green), 
G (black), C (blue), or U (red) in the grid. Semi-transparent colors in two positions in the same sgRNA 
indicate that deletions can be interpreted at either of adjacent positions (also marked by “or”) due to 
identical nucleotides at both positions. The bar graph on the right shows cleavage activity aligned to 
the corresponding sgRNA variants using the same color scheme. Positions relative to PAM are labeled 
on the y-axis. The vertical dashed lines mark the activity levels of the original sgRNAs. Error bar, 
s.e.m. (n=2). 
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sequence from the PAM (Figure 45). Note that due to the presence of consecutive 
identical nucleotides at positions 1 and 2, 6 and 7, removing either one of the identical 
nucleotides in the sgRNA at these adjacent positions would give the same sequence and 
have the same sgRNA-DNA interface (their position is therefore marked as “or” in 
Figure 45). In contrast, -1nt variants of R-30 induced variable cleavage activity at more 
positions throughout the guide sequence: positions 1, 2 or 3, 7, 8, 9 or 10, 11, 16, 17, 18, 
and 19 from the PAM (Figure 45). Seven R-30 variants have activities comparable to or 
even higher than that of the original sgRNA. These variants correspond to DNA bulges at 
positions 1, 2 or 3, 8, 9 or 10, 11, 18, and 19 from the PAM (Figure 45). Consistent with 
previous studies showing that the specificity of CRISPR/Cas9 systems is guide-strand 
and target-site dependent (5,51,52), the positions in R-01 sgRNA variants where DNA-
bulges were tolerated are different from that in R-30 sgRNA variants. However, these 
positions seem to group in the 5’-end, middle, and 3’-end regions of the target loci, as in 
both R-01 and R-30 sgRNA-DNA interfaces, single-base DNA-bulges at the following 
five positions seems to be tolerated: positions 1, 2, 7, 18, and 19. Although additional 
studies are needed to determine if these positions are common for different target 
sequences, single-base DNA-bulges at the target sites corresponding to these positions 
may be worth investigating when performing off-target analysis for CRISPR/Cas9 
systems. 
 In certain cases, off-target sites with DNA bulges may also be interpreted as 
sequences having various base mismatches with guide sequence and/or PAM (6). For 
example, the sgRNA-DNA interfaces corresponding to removing 5’-end  bases in the 
guide sequences (positions 18 and 19 of the R-01 interface, and 16-19 of the R-30 
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interface) can be viewed as having DNA bulges or having mismatches in the 5’-end 
region of sgRNA, which have been shown to be better tolerated compared to the 3’-end 
region (17,51,52). Therefore, the Cas9 cleavage activities induced by these guide strands 
may be interpreted as tolerance of base mismatches at the 5’-end of the guide RNA. In 
addition, the position -1 variant of R-30 results in a shift in the adjacent PAM from GGG 
to CGG (another canonical PAM), which could explain why the activity of this guide 
sequence variant was similar to the original R-30. However, off-target activities 
associated with most other DNA bulges for the R-01 and R-30 interfaces cannot be 
attributed to base mismatch tolerance, since a base removal in the sgRNAs 
(corresponding to a DNA bulge) could result in many base mismatches or mutation in the 
PAM sequence. For example, the cleavage activity induced by the R-01 variant at 
position 2/1 may be alternatively interpreted as Cas9 cleavage with a GTG PAM (Figure 
45), which is highly unlikely according to previous studies (52,53). Further, a R-30 guide 
strand variant at position 11 would contain at least seven mismatches if modeled without 
a bulge. This guide strand resulted in a 1.8-fold higher cleavage activity compared to the 
original R-30 (Figure 45), which cannot be readily explained by the high level of base 
mismatches (which should prohibit cleavage), and thus should be attributed to the 
tolerance of DNA bulges.  
Cas9 cleavage with small sgRNA truncations  
 We further investigated if sgRNAs with small truncations at the 5’-end retain 
cleavage activity. One to six nucleotides were deleted from the 5’ end of R-01 except for 
the nucleotide at position 20, because the guanine here is required for the expression 
under the U6 promoter (Figure 46). For these guide sequence truncations, we found that 
 108
1- to 2-bp 5’ truncations could still induce cleavage activities similar to the full-length 








Cas9 cleavage with sgRNA variants containing single-base sgRNA bulges 
 In addition to Cas9 induced cleave at off-target sites with single-base DNA 
bulges, we further investigated if single-base sgRNA bulges (that model single-base 
deletions in DNA sequence) could induce Cas9 cleavage (Figure 44b). Again, using 
sgRNA-DNA interfaces R-01 and R-30 as model systems, we systematically added single 
nucleotides at positions throughout the original guide sequences, so that the interfaces 
with target sequences in HBB or CCR5 carries single-base sgRNA bulges (Figure 47 and 
Figure 48). For some positions, the addition of single nucleotide A, C, G and U 
respectively to the guide sequence was all tested to account for the effect of base identity. 
Figure 46: Activity for sgRNAs containing 5’-end truncations. 
(a) 1-6 bp truncations at the 5’ end of the guide sequence R-01 targeted to the HBB gene. (b) Activity 
for truncated sgRNAs. Truncated positions are highlighted in gray in the grid. Bar graph shows 
corresponding cleavage activity measured by T7E1 assay in HEK293T cells. Error bar, s.e.m. (n=2). 
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As above, HEK293T cells were transfected with plasmids of the Cas9 and sgRNA 









Figure 47: Activity of R-01 sgRNA variants targeted to genomic locus of HBB to make single-base 
sgRNA bulges. 
Single nucleotide, A (green), G (black), C (blue), or U (red), was inserted into the original sgRNA 
throughout the guide sequence. Sequence of the original sgRNA is in the top row of the grid. Positions 
of the original guide sequence are shaded in gray, while the inserted positions are white. Due to 
identical nucleotides at adjacent positions, some inserted nucleotides can be in multiple positions 
(marked by “or”). Bar graphs on the right show corresponding cleavage activities quantified by T7E1 
assay in HEK293T cells, with the same color scheme for different inserted nucleotides. Positions 






 We found that sgRNA bulges in the R-30 sgRNA-DNA interface were better 
tolerated compared to those of R-01. In contrast to the tolerances of DNA bulges adjacent 
to the PAM, sgRNA bulges close to the PAM prohibited cleavage. For the R-01 interface, 
single-base sgRNA bulges between each of the 11 PAM-proximal guide-strand 
nucleotides resulted in no detectable activity (Figure 47). Single-base sgRNA bulges of 
the four nucleotides closest to the PAM in R-30 also eliminated T7E1 activity (Figure 
48). The sgRNA bulges 3’ to the position 11 in R-30 resulted in reduced cleavage 
activities (Figure 48). The lack of activity with PAM-proximal sgRNA bulges in R-01 
and low levels of activity with PAM-proximal sgRNA bulges in R-30 are consistent with 
the reduced mismatch tolerance in the “seed sequence” reported in previous studies 
Figure 48: Activity of R-30 sgRNA variants targeted to genomic locus of CCR5 to make single-base 
sgRNA bulges. 
See the figure above for explanation.
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(17,41,83). Nucleotides additions in sgRNA sometimes created consecutive identical 
nucleotides, such as adding a G before or after position 14 of R-01 or before or after 
position 15 of R-30. These sgRNA variants model a G-bulge that can be at either position 
in the sgRNA (Figure 47). We found that in many cases sgRNA bulges with a single U 
gave rise to high nuclease activities. Among all sgRNA variants with activities higher 
than the original sgRNAs, ~71% (5/7) were targeted to the loci with a U-bulge. Overall, 
single-base sgRNA bulges induced higher Cas9 cleavage activities at many more 
positions than that with single-base DNA bulges. This is not surprising since RNA 
molecules are more flexible than DNA molecules, thus having smaller binding energy 
penalty with single-base RNA bulges, resulting in a higher tolerance (84).   
 RNA-DNA interfaces with single-base RNA bulges can also be viewed as 
sequences with various mismatches in the guide sequence and PAM (6). Specifically, 
sgRNA bulges at the 5’-end of guide RNA sequences (e.g. U+20/19 for R-01 and R-30 
interfaces) can be alternatively viewed as having one to a few base mismatches with the 
3’-end of DNA sequences (6), which are often tolerated, similar to deletions of 1-2 bp at 
the 5’ end of guide strands (Figure 46).  SgRNA bulges close to the 3’-end of guide 
sequence can be alternatively viewed as having base mismatches in the 3’-end region, 
including those at the third base of PAM (R-30 variants) (the last six variants in 
Supplementary Figure S2 of reference (6)). Among all sgRNA variants with considerable 
activities, most of them could not be explained by tolerance of base mismatches, since 
they would contain more than five mismatches or change in the third base of PAM, which 







The effect of GC content of sgRNAs on the tolerance of single-base sgRNA bulges 
 As revealed in our study, the specificity profile (location and level of off-target 
cleavage) of R-01 variants is substantially different from that of R-30 variants. R-30, 
 
Figure 49: Activity of sgRNA variants with bulges targeted to genomic loci with different GC 
contents. 
(a) Target sites, cleavage activities (% indels by T7E1 assay), and GC contents of different guide 
strands targeted to HBB and CCR5 genes. Cleavage activity of R-25 is from reference (5). (b-c) T7E1 
Activity of R-08 variants targeted to HBB genomic loci with (B) single-base DNA bulges or (c) single-
base sgRNA bulges. Color schemes and labels are similar to the figures above. Error bar, s.e.m. (n=2). 
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which showed a higher level of tolerance to DNA and RNA bulges than R-01, has a GC 
content of 70%, whereas R-01 has a GC content of 50%. We hypothesized that the GC 
content of guide strands R-01 and R-30 played a significant role in causing this 
difference. To investigate this hypothesis, we tested two additional sets of guide strands 
targeted to HBB and CCR5 genes respectively, with different GC contents compared to 
R-01 and R-30 (Figure 49). Specifically, R-08 has a moderately higher GC content 
compared to R-01 (65% compared to 50%), whereas the GC content of R-25 is half of 
that of R-30 (35% compared to 70%). Cas9 induced cleavage with sgRNA variants of R-
08 and R-25 was individually tested to quantify the bulge tolerance in HEK 293T cells. 
 For the guide strand R-25, which contains a low percentage of GC, we found that 
all R-25 variants tested showed non-detectable activities using the T7E1 assay 
(Supplementary Table S2 of reference (6)). In contrast, for R-08 variants with bulges 
throughout the guide sequence, we observed cleavage activities at more positions 
compared with R-01 (Figure 49). These results of bulge tolerance for variants of R-08 
and R-25 support our GC dependence hypothesis. 
Cas9 cleavage with sgRNA variants containing 2-bp to 5-bp bulges 
 In addition to single-base bulges between sgRNA and target sequence, it is 
important to determine if bulges longer than 1 bp can also be tolerated by the 
CRISPR/Cas9 systems. Consequently, the tolerance of 2-bp to 5-bp bulges was tested at 
locations where single-base bulges were well tolerated. For sgRNA bulges, we added two 
to five U’s 15-bp or 12-bp upstream of PAM into the guide sequences of R-01 and R-30, 
respectively. To generate DNA bulges, we deleted two bases from the guide sequences of 
R-01 and R-30 (Figure 50a). Strikingly, we found that sgRNA variants forming 2-bp, 3-
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bp, and 4-bp RNA bulges induced cleavage activities as determined by the T7E1 assay in 
HEK 293T cells (Figure 50b). Since sgRNA variants forming 2-bp DNA bulges did not 
show any detectable activity, we did not test longer DNA bulges. Our findings that 
sgRNA bulges of > 2-bp are better tolerated than DNA bulges of similar size are 
consistent with the higher cleavage activities by guide strands with 1-bp sgRNA bulges 










Figure 50: Activity of sgRNA variants with 2-bp DNA or 2-bp to 5-bp sgRNA bulges. 
Guide strands with 2-bp to 5-bp addition are labeled with “+” and positions of the added bases, and 
guide strands with 2-bp deletion are labeled with “-“ and positions of the deleted bases. (a) Sequences 
comparison of guide RNAs and target sites, with position numbers on top. (b) Bar graph showing 







Cleavage by paired Cas9 nickases with sgRNA variants containing single-base 
bulges 
 Paired Cas9 nickases (Cas9n) were recently developed to generate DNA double-
strand breaks by inducing two closely spaced single-strand nicks using an appropriately 
designed pair of guide RNAs (54,85). This strategy may lower the off-target cleavage, as 
DSBs could occur only when both guide RNAs of the pair result in nearby nicks at the 
 
Figure 51: Paired Cas9 nickases with one bulge-containing sgRNA effectively cleave genomic DNA. 
(a) Human HBB gene targeted by Cas9 nickases (Cas9n) with paired guide strands R-01 and R-02. 
PAMs are indicated with red bars. (b) T7E1 activities of Cas9n with R-01 bulge-variants paired with 
R-02, compared with original Cas9 activities of the R-01 bulge-variants as in Figure 2 and Figure 4. 
Error bar, s.e.m. (n=2). Asterisks indicate P-values from a two-tailed independent two-sample t-test. 
*P < 0.05, **P < 0.01, ***P < 0.001.
 117
same time. Here we tested if paired Cas9n systems can tolerate bulges by using one 
bulge-forming guide variant paired with a perfectly matched guide strand. Specifically, 
four variants of R-01 showing high activities with Cas9 were paired with R-02, including 
R1 U+14/13 and R1 C+12 to test sgRNA bulges, and R1 -7/6 and R1 -2/1 to test DNA 
bulges.  Each paired sgRNAs created a 34-bp 5’ overhang in the HBB gene (Figure 51) 
(5), and the Cas9n cleavage activities were determined by the T7E1 assay. We found that 
both sgRNA and DNA bulges were well also tolerated in the Cas9n system (Figure 51). 
The paired Cas9 nickases with single sgRNA bulges showed activities comparable to 
Cas9 system having one bulge in R0-1; however, for DNA bulges, the activities of paired 
Cas9 nickases were >2-fold higher than Cas9.   
Cas9 cleavage at genomic loci with both base mismatches and DNA or sgRNA 
bulges 
 To gain a better understanding of CRISPR/Cas9 off-target activity, we examined 
27 different sgRNAs targeting 6 different genes (Table 10), 7 targeted HBB, 2 for EGFP, 
5 for CCR5, 7 for ERCC5, 4 for TARDBP and 2 for HPRT1 respectively. We performed 
off-target analyses of these sgRNAs by searching the human genome for potential off-
target sites and found that for the sgRNAs searched, single-base DNA or sgRNA bulges 
were not located without mismatches in the human genome. Therefore, for each sgRNA, 
we selected a subset of the potential sites with one to three mismatches and avoided 
mismatches close to the PAM as much as possible. All of these sgRNAs efficiently 
induced mutations at their intended target loci in human HEK293T cells, as measured by 
the T7E1 assay (Figure 52). Using the T7E1 assay, we initially investigated 18 potential 
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off-target sites containing target-site insertions and 62 containing deletions 









Figure 52: T7E1 assay measuring the on-target endogenous gene modification efficiency of sgRNAs 
in HEK293T cells. 
Lane headings indicate the target genes and the sgRNA index names. “-” denotes samples transfected 
with a stuffer plasmid. Numbers below each lane having detectable activity show the percentage of 
modified alleles. Primers used for the PCR amplification are listed in Supplementary Table S3 of 
reference (6). 
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 Cas9 induced cleavage activities in CCR5 and ERCC5 respectively were detected 
for two off-target sites each bearing one DNA bulge and one mismatch (Figure 53). For 
R-30, the identified off-target site R-30 Off-4 contains a single-base DNA bulge at 
position 5, 6, or 7 and a base mismatch at position 14. The off-target gene modification 
rate determined by T7E1 is 9%, almost one third of the 30% on-target activity at the 
CCR5 gene (Figure 53). For an R-31 off-target site with a single-base DNA bulge at 
position 2 and a mismatch at position 20, the off-target gene modification rate determined 
by T7E1 was 3%, compared to 60% on-target activity at the ERCC5 gene (Figure 53). 
Due to the high frequency of small indels that result from repair of Cas9 induced 
cleavage, which may be poorly detected by the T7E1 assay, we verified the mutagenesis 
at these off-target sites using Sanger sequencing (Figure 53). For both off-target sites, the 
mutation frequencies quantified by Sanger sequencing are higher than those by T7E1, 
which is consistent with a previous study (5). We did not observe any off-target cleavage 
for the 62 sites tested with both sgRNA bulge and base mismatch, although in our model 
systems with sgRNA bulges only, high cleavage activities were observed (Figure 47 and 
Figure 48). This discrepancy suggests that sites forming sgRNA bulges may be less 









Figure 53: Activities of CRISPR/Cas9 nucleases for genomic target sites and for off-target sites with 
single-base DNA bulges coupled with mismatches. 
(a-b) On-target and off-target cleavage activities for (a) sgRNAs R-30 targeted to CCR5 gene, and (b) 
R-31 target to ERCC5 gene. Upper: target sequences (CCR5 and ERCC5) and off-target sequences 
(Off-4 and Off-1) with mismatch (red) and DNA bulge (shaded in yellow) are shown next to the 
sgRNA (R-30 and R-31) tested. Red lines indicate the PAM. Bottom: Cleavage activities at the target 
sites and off-target sites measured by T7E1 assay in HEK293T cells. Numbers below the lanes 
indicate average percentages of gene modification (n=2). Asterisks indicate specific T7E1 cleavage 
products. (c-d) Sanger sequencing reads of amplified off-target sites aligned to the wild-type genomic 
sequence and sgRNAs for (c) R-30 and (d) R-31. The occurrence of each sequence is indicated to the 
left of the alignment, if greater than one. Unmodified reads are indicated by “WT”. Deletions are 
marked in gray, and insertions marked in yellow. 
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 Two genomic off-target sites for guide strand R-30, Off-4 and Off-5, have 
identical target sequences (Figure 54), but were cleaved at different rates. Specifically, R-
30 Off-4 had a cleavage rate of 9%, while the cleavage at Off-5 was undetectable with 
the T7E1 assay (Figure 54). Sanger sequencing revealed a 45.5% mutation rate at the R-
30 Off-4 locus (Figure 53c), compared to a 4.2% mutation rate at R-30 Off-5 (Figure 54). 
Since R-30 Off-4 and R-30 Off-5 sites have identical sequences, our results clearly 
suggest that off-target cleavage of Cas9 nuclease is very dependent on genomic context 
(5). Further investigation of these two sites using the ENCODE annotation from UCSC 
genome browser (86,87) revealed that R-30 Off-4, which had high off-target activity, 
targeted a site within 400 bp of the 3’ end of a long non-coding RNA (RP4-756H11.3) 
and 12kb of the protein-coding gene RABGEF. Analysis of the ENCODE data for 
chromatin structure in normal human embryonic kidney cells (NHEK) cells, the cell type 
of origin for the HEK293 cells used in this study shows Off-4 to be within 3kb of a strong 
enhancer (marked by H3K27Ac and H3K4me1) and a strong DNAse1 hypersensitive 
site, suggestive of an open chromatin structure. In contrast, R-30 Off-5, which had low 
activity, targeted a site in a 162-kb intergenic region between the WBSCR28 and ELN 
genes that is marked by the more heterochromatic H3K27me3, and hence may be less 
accessible for Cas9 induced cleavage (Figure 55). Taken together, these data strongly 
suggest that differences in the local chromatin structure may underlie the observed 













 We further performed deep sequencing at 55 putative off-target sites 
corresponding to single-base sgRNA bulges and 21 sites corresponding to single-base 
Figure 55: Histone modification status and annotation of R30 Off-4 and Off-5 loci obtained from the 
UCSC genome browser. 
Figure 54: Off-target cleavage of R30 Off-5 quantified by (a) T7E1 assay and (b) Sanger sequencing. 
“-” and “+” denote samples treated without and with nuclease, respectively. The occurrence of each 
sequence is indicated to the left of the alignment, if greater than one. Unmodified reads are indicated 
by “WT”. Deletions are marked in gray, and insertions marked in yellow. 
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DNA bulges. The sites were amplified from genomic DNA harvested from HEK 293T 
cells transfected with Cas9 and sgRNAs (Supplementary Table S6 of reference (6)). The 
55 sites with sgRNA bulges contain 35 sites tested in the preliminary T7E1 assay, and the 
21 sites with DNA bulges include seven sites tested in the T7E1 assay. Putative bulge-
forming loci containing one to three PAM-distal mismatches were chosen, since we did 
not find sites associated with a bulge without any base mismatch. We also selected some 
of the bulge-forming sites with a high level of sequence similarity, but containing an 
alternative NAG-PAM. For comparison, the deep sequencing also investigated 16 on-
target sites of the sgRNAs tested. Each locus was sequenced from mock-transfected cells 
as control.  
 We identified additional 13 bulge-forming off-target sites with significant 
cleavage activities resulted from CRISPR/Cas9 systems compared to the mock-
transfected samples (Figure 56). We found that the number of genomic off-target 
cleavage sites associated with sgRNA bulges was relatively small (some of these cases 
are indistinguishable from a few mismatches at 5’ end), but there was considerable 
activity at genomic sites with DNA bulges coupled with one to three additional base 
mismatches, even with an alternative NAG-PAM. Similar results showing more off-target 
effect with DNA bulges plus mismatches compared to sgRNA bulges plus mismatches 
were observed in the preliminary T7E1 assay ( Figure 53).  The positions of these 
tolerated DNA bulges are 1-3 bp and 7-10 bp from PAM, consistent with the results from 
the model systems using sgRNA variants. The majority of the sites with off-target 
activities detected, as shown in Figure 53 and Figure 56 are associated with the sgRNA 
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R-30, which has a high GC content (70%). Other sgRNAs that resulted in off-target 








5.3  Discussion 
 Although CRISPR/Cas9 systems can efficiently induce gene modification in 
many organisms, recent studies revealed that off-target cleavage may occur in 
mammalian cells with up to five-base mismatches between the short ~20-nt guide RNA 
Figure 56: Significant activities analyzed by deep sequencing at genomic off-target loci containing 
bulges coupled with mismatches and alternative NAG-PAM. 
Only bulge-containing off-target loci determined to have P-values less than 0.05 are shown. Table on 
the left shows numbers of mismatches at off-target loci in addition to bulge (# of mis), bulge types, 
positions of bulges from PAM (bulge pos), labels for the loci as in Supplementary Table S6 of 
reference (6), and sequences of off-target sites including PAMs. In these off-target genomic sequences, 
mismatches are marked by red, deleted base compared to sgRNA marked as “-“ (sgRNA bulge), 
inserted base compared to sgRNA marked as underlined red letters (DNA bulge), NAG-PAMs are 
marked by blue. Bar graph on the right indicates indel percentages quantified for mock (blue) and 
treated samples (red) with sgRNAs at off-target loci shown in the table to the left. Error bars, Wilson 
intervals (Materials and Methods). *P ≤ 0.05, ***P ≤ 0.001 as determined by Fisher’s exact test. 
The % indel values of treated samples are also indicated. 
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and DNA sequences (5,51-53). Here we show that CRISPR/Cas9 systems can have off-
target cleavage when DNA sequences have an extra base (DNA bulge) or a missing base 
(sgRNA bulge) at various locations compared with the corresponding RNA guide strand. 
Importantly, our results revealed that, sgRNA bulges of up to 4-bp could be tolerated by 
CRISPR/Cas9 systems (Figure 50). The correlation between cleavage activity and the 
position of DNA bulge or sgRNA bulge relative to the PAM appears to be loci and 
sequence dependent when comparing the specificity profiles of guide sequences R-01 and 
R-30.  
 Our results suggest the need to perform comprehensive off-target analysis by 
considering cleavage due to DNA and sgRNA bulges in addition to base mismatches. We 
believe that the following design guidelines will help reduce potential off-target effects of 
CRISPR/Cas9 systems: (i) conservatively choose target sequences with relatively low GC 
contents (e.g. ≤35%), (ii) avoid target sequences (with either NGG- and NAG-PAM) with 
≤3 mismatches that form DNA bulges at 5’ end, 3’ ends or around 7-10 bp from PAM, 
and (iii) if possible, avoid potential sgRNA bulges further than 12 bp from PAM. To aid 
the rational design of sgRNAs for an intended DNA cleavage site, as well as 
experimental determination of off-target activity, a robust bioinformatic tool that 
incorporating these design guidelines and ranking potential off-target sites is desired, and 
more extensive studies of off-target cleavage by CRISPR/Cas9 systems may be needed 
concerning the dependence of off-target activity on the type (base mismatch, DNA bulge, 









 We found that different specificity profiles of R-01 and R-30 guide sequences 
(and variants) are not due to different expression levels of the sgRNAs. Quantitative PCR 
of inactive R-01 variants and active R-30 variants indicated similar sgRNA expression 
levels (Figure 57). We believe that high GC-content, which makes the RNA/DNA 
hybrids more stable (88), may be responsible for increased tolerance of DNA bulges and 
sgRNA bulges. Consistent with our hypothesis, guide strand R-30 (70% GC) showed the 
highest tolerance to sgRNA and DNA bulges among the four guide strands we tested (R-
01, R-08, R-25 and R-30), while guide strand R-25 (35% GC) does not seem to tolerate 
any bulges. Guide sequences showing bulge-related off-target activity in Figure 53 and 
Figure 56 all have GC contents ≥50%, which further confirms that it is important to 
 
Figure 57: Quantitative PCR of sgRNA expression levels in HEK293T cells for R-01 and R-30 
variant. 
Relative expression of these sgRNAs was quantified using the ddCt method (see “Material and 
Methods”). 
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consider DNA-bulges for sgRNAs with high GC content, even with up to three base 
mismatches, when investigating off-target effects. 
 As shown in Supplementary Figure S1 and S2 of reference (6), bulges in the PAM 
distal or PAM proximal regions can reflect either mismatch tolerance or RNA/DNA 
bulge tolerance. Off-target sites containing these bulges may also be present in the output 
of a search considering mismatches only. In either scenario, these sites should be tested 
for off-target cleavage. A recent study reveals that a Cas9 ortholog from Streptococcus 
thermophilus has a PAM located 2 bps downstream of the protospacer (89). Instead of 
forming a DNA-bulge, the cleavage resulting from the variant R-01 -2/1 (Supplementary 
Figure S1 of reference (6)) may alternatively reflect the tolerance of a linker between the 
target sequence and PAM. Further studies are needed to distinguish between these two 
scenarios. On the other hand, bulges in the middle of the target sequence are likely to 
reflect only the tolerance of RNA or DNA bulges. Since there would be too many 
mismatches if bulges are not formed, potential off-target sites with bulges in the middle 
are not likely to be included in the output of a search allowing mismatches only. Though 
the mechanisms for bulge tolerance has yet to be determined, there is a need to 







Figure 58: Indel spectra for original sgRNAs and sgRNA variants of R-01 determined using deep 
sequencing. 
The change in bases at predicted cut sites resulting from indicated sgRNAs was calculated from ~104 
reads per sample. The y-axis represents percentages in all indel-reads for that sgRNA. Overall % indel 







Figure 59: Indel spectra for original sgRNAs and sgRNA variants of R-30 determined using deep 
sequencing. 
The change in bases at predicted cut sites resulting from indicated sgRNAs was calculated from ~104 
reads per sample. The y-axis represents percentages in all indel-reads for that sgRNA. Overall % indel 
in total reads are indicated in each graph. 
 130
 An interesting finding from this study is that sgRNA variants with bulges had 
different indel spectra than sgRNA without bulges (Figure 58 and Figure 59). We 
quantified indel spectra for original sgRNAs R-01 and R-30, as well as sgRNA variants 
R1 -7/6, R1 C+12, R30 -11, and R30 U+12, using deep sequencing with around 104 reads 
for each sample. Bulge-forming sgRNA variants showed higher ratios of larger deletions 
(-10 or -7), whereas the original sgRNAs without bulges generate mostly 1-bp insertions. 
This effect is more prominent for variants forming sgRNA bulges (R1 C+12 and R30 
U+12). Bulge-forming sgRNA variants may be more effective than regular sgRNAs at 
creating larger deletions that may be preferred in certain applications , such as targeted 
disruption of genomic elements. 
 Recently, paired Cas9 nickases have been shown to increase target specificity of 
CRISPR/Cas9 systems. However, only off-target activity associated with single guide 
RNAs were investigated (54,85), and the effect of cooperative nicking at potential off-
target sites with sequence similarity to a pair of guide RNAs has not been characterized. 
We showed that Cas9n is able to cleave efficiently at target sites despite a single-base 
bulge in one of the paired guide RNAs. The results of this work provide some insight into 
off-target cleavage of the paired Cas9 nickases, since nicking of opposite DNA strands is 
likely to be independent events, and the knowledge of bulge tolerance at the sgRNA-
DNA interface would be applicable to off-target cleavage of Cas9 nickases. 
 Recent studies on the specificity of CRISPR/Cas9 systems revealed that a broad 
range of partial matches between sgRNA and DNA sequences could induce off-target 
cleavage (5,51-53), which may limit the choice of sgRNA designs. While the use of 
bioinformatic tools for predicting potential off-target loci based on sequence similarity 
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may be useful, our results suggest that partially matched sequences including base 
mismatches, deletions and insertions needs to be considered.  Since there might be a large 
number of potential off-target sites due to the many partially matched sequences, and the 
effect of sgRNA-DNA sequence differences on off-target cleavage is target-site and 
genome-context dependent, experimentally determining true off-target activities is 
necessary, including the use of deep sequencing. 
5.4  Materials and methods 
CRISPR/Cas9 plasmid assembly 
 DNA oligonucleotides containing a G followed by a 19-nt guide sequence (Table 
10) were kinased, annealed to create sticky ends, and ligated into the pX330 plasmid that 
contains the +85 chimeric RNA under the U6 promoter and a Cas9 expression cassette 
under the CBh promoter (kindly provided by Dr. Feng Zhang; it is also available at 
Addgene) (90). Variants of sgRNAs were constructed and tested with 1 or more 
nucleotides inserted or deleted (Supplementary Table S2 of reference (6)). The annealed 
oligonucleotides have 4-bp overhangs that are compatible with the ends of BbsI-digested 
pX330 plasmid. Constructed plasmids were sequenced to confirm the guide strand region 
using the primer CRISPR_seq (5’-CGATACAAGGCTGTTAGAGAGATAATTGG-3’). 
T7 endonuclease I (T7E1) mutation detection assay for measuring endogenous gene 
modification rates 
 The cleavage activity of RNA-guided Cas9 at endogenous loci was quantified 
based on the mutation rates resulting from the imperfect repair of double-stranded breaks 
by NHEJ. In a 24-well plate, 60,000 HEK293T cells per well were seeded and cultured in 
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DMEM media supplemented with 10% FBS and 2 mM fresh L-glutamine, 24 hours prior 
to transfection. Cells were transfected with 750 ng (sgRNA variants) or 1000 ng of 
CRISPR plasmids using 3.4 µl FuGene HD (Promega), following manufacturer’s 
instructions. Each sgRNA plasmid was transfected as biological duplicates in two 
separate transfections.  All subsequent steps, including the T7E1 assay were performed 
independently for the duplicates. A HEK293T-derived cell line containing stably 
integrated EGFP gene was used for sgRNAs targeted to the EGFP gene. This cell line 
was constructed by correcting the mutations in the EGFP gene in the cell line 293/A658 
(91) (kindly provided by Dr. Francesca Storici). The genomic DNA was harvested after 3 
days using QuickExtract DNA extraction solution (Epicentre), as described in (58). T7E1 
mutation detection assays were performed, as described previously (2) and the digestions 
separated on 2% agarose gels. The cleavage bands were quantified using ImageJ. The 
percentage of gene modification = 100x (1 – (1-fraction cleaved)0.5), as described (58). 
Unless otherwise stated, all PCR reactions were performed using AccuPrime Taq DNA 
Polymerase High Fidelity (Life Technologies) following manufacturer’s instructions for 
40 cycles (94 °C, 30 s; 60 °C, 30 s; 68 °C, 60 s) in a 50 µl reaction containing 1.5 µl of 
the cell lysate, 3% DMSO, and 1.5 µl of each 10 µM target region amplification primer 
(Supplementary Table S3 of reference (6)) or off-target region amplification primer 
(Supplementary Table S4 of reference (6)).  
Sanger sequencing of gene modifications resulted from Cas9 
 To validate the mutation rates measured by T7E1 assay, the PCR products used in 
the T7E1 assays were cloned into plasmid vectors using TOPO TA Cloning Kit for 
Sequencing (Life Technologies) or Zero Blunt TOPO PCR Cloning Kit (Life 
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Technologies), following manufacturer’s instructions. Plasmid DNAs were purified and 
Sanger sequenced using a M13F primer (5’-TGTAAAACGACGGCCAGT-3’). 
Identification of off-target sites 
 Potential off-target sites in the human genome (hg19) were identified using 
TagScan (http://www.isrec.isb-sib.ch/tagger), a web tool providing genome searches for 
short sequences (92). Guide sequences containing single-base insertions (represented 
with an “N” in the sequence) and single-base deletions at different positions were 
entered, followed by the PAM sequence “NGG”. We alternatively searched for off-target 
sites using the recently developed bioinformatics program COSMID that can identify 
potential off-target sites due to insertions and deletions between target DNA and guide 
RNA sequences (Cradick, et al. submitted). Primers were individually designed to 
amplify the genomic loci identified in the output. 
Quantitative PCR to measure the expression levels of different guide RNAs 
 HEK 293T cells were transfected with 750 ng sgRNA variants, as described 
above. Each sgRNA was transfected as biological triplicates in three separate wells, and 
processed independently. Total RNA was isolated from cells using the RNAeasy kit 
(Qiagen). Extracted RNA was reverse-transcribed using the iScript cDNA Synthesis  
(BioRad). The cDNA was amplified using the iTaq Universal SYBR Green Supermix 
(BioRad) and analyzed with quantitative PCR using specific primers that annealed at 
60°C (Supplementary Table S3 of reference (6)). Quantitative PCR was performed in 
technical triplicates for each cDNA sample from single transfected well. Relative mRNA 
expression was analyzed using an MX3005P (Agilent) and normalized to glyceraldehyde-
 134
3-phosphate dehydrogenase (GAPDH) expression. GAPDH expression remained 
relatively constant among treatments.  
 Relative mRNA expression of target genes was calculated with the ddCT method. 
All target genes were normalized to GAPDH in reactions performed in triplicate. 
Differences in CT values (ΔCT = CT gene of interest−CT GAPDH in experimental 
samples) were calculated for each target mRNA by subtracting the mean value of 
GAPDH. ΔCT values were subsequently normalized to the reference sample (mock 
transfected cells) to get ΔΔCT or ddCT (relative expression = 2-ΔΔCT). 
Deep sequencing to determine activities at genomic loci 
 Genomic DNAs from mock and nuclease-treated cells that were prepared for 
T7E1 assays were used as templates for the first round of PCR using locus-specific 
primers that contained overhang adapter sequences to be used in the second PCR 
(Supplementary Table S5 and S6 of reference (6)). PCR reactions for each locus were 
performed independently for 8 touchdown cycles in which annealing temperature was 
lowered by 1 °C each cycle from 65 °C to 57 °C, followed by 35 cycles with annealing 
temperature at 57 °C. PCR products were purified using Agencourt AmPure XP 
(Beckman Coulter) following manufacturer’s protocol. The second PCR amplification 
was performed for each individual amplicon from first PCR using primers containing the 
adapter sequences from the first PCR, P5/P7 adapters, and sample barcodes in the reverse 
primers (Supplementary Table S5 of reference (6)). PCR products were purified as in first 
PCR, pooled in an equimolar ratio, and subjected to 2X250 paired-end sequencing with 
an Illumina MiSeq.  
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 Paired-end reads from MiSeq were filtered by an average Phred quality (Q score) 
greater than 20, and merged into a longer single read from each pair with a minimum 
overlap of 10 nucleotides. Alignments were performed using Borrows-Wheeler Aligner 
(BWA) for each barcode (93), and percentage of insertions and deletions containing 
bases within a ±10-bp window of the predicted cut sites were quantified. Error bounds for 
indel percentages are Wilson score intervals calculated using binom package for R 
statistical software (version 3.0.3) with a confidence level of 95% (76). To determine if 
each off-target indel percentage from a CRISPR-treated sample is significant compared 









CHAPTER 6: CONCLUSIONS AND FUTURE PERSPECTIVES 
 Genome engineering can be used to create user-defined cells or organisms to 
serve our needs. For example, genetically modified cells can be used to produce 
biopharmaceutical reagents (94); engineered cells and organisms can be used as disease 
models(11); gene-modifying reagents can potentially be delivered into cells to correct 
diseases; gene function can by studied by knocking out genes. TALENs and CRISPRs are 
two powerful genome engineering tools developed in the past several years, and 
substantially accelerate genome modification and allow us to engineer a large variety of 
organisms even including pigs, cows, and monkeys. Despite The ease to design and make 
these nucleases, it is still challenging to simultaneously achieve both high efficiency and 
high specificity with these nucleases. This thesis studied the activity and specificity of 
TALENs and CRISPRs, and generated tools and guidelines to effectively improve these 
two aspects. 
 Architecture of TALEN was examined to help researchers choose the suitable 
architecture for balanced activity and specificity. A Scoring Algorithm for Predicting 
TALEN Activity (SAPTA) was developed to screen for active TALENs in silico. Finally, 
we identified the unexpected off-target effect of a recently developed nuclease, 
CRISPR/Cas9 system. This finding allows the selection of more specific CRISPRs for 
safer gene modification in cells. The optimization of engineered nucleases in this thesis 
provides powerful and reliable tools for genome engineering as a way to treat and model 
diseases.  
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 While there is not a perfect nuclease with consistently high efficiency and 
specificity in genome engineering, we can choose different versions of nucleases to 
accommodate our needs in different applications. For example, if high specificity is 
needed in clinic, we can use TALENs which have less off-target effect. If a high-
throughput genome-wide knock-out of a large number of genes is desired, CRISPRs can 
be used due to the capability to make CRISPRs in large-scale (95). By carefully selecting 
target sites to avoid similar sequences in the genome, we can also obtain more specific 
nucleases. This approach is relatively easy with TALENs since the target sequences of 
TALENs are in the range of 30-50 nt, so similar sequences are rare in the human genome.  
 A variety of nuclease architectures are also developed to overcome the off-target 
problem. Obligate hetero-dimeric TALENs(96) would not cut DNA when the same 
TALENs pair with itself (homo-dimer), and thus eliminate homo-dimeric off-target 
cleavage. Cas9 nickases cooperatively generate DSBs using two guide RNAs, thus 
increasing the target length and reducing potential off-target sites in the genome (54,85). 
Inactivated Cas9 was fused to FokI nuclease domain to further increase target 
specificity(97). The large size of Cas9 expression cassette (around 5.5 kb) hinders 
effective packaging of CRISPR/Cas9 system into Adeno-associated viruses (AAV). 
Smaller Cas9 and promoter, splicing systems of protein or RNA are being investigated to 
enable the AAV packaging of CRISPR/Cas9. Future optimization of CRISPR/Cas9 
specificity and delivery will likely affect whether this tool can be used in clinical 
applications.  
 Besides engineered nucleases which cleave DNAs and change genomes, other 
effector domains can be fused to the DNA binding domains of Transcription-Activator-
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Like (TAL) effectors or Cas9 to regulate gene expression or modify epigenetic markers. 
Activator and repressor domains have been linked with TAL domain and inactivated 
Cas9 to increase or decrease gene expression (50,98).  Demethylation domain was linked 
to TAL domain to demethylate CpG regions(99). More genome engineering tool kits will 
likely be developed in the near future to facilitate fundamental research and clinical 
applications.  
 We have used these genome-engineering tools in numerous collaborations for 
disease-related research. The applications include genetic treatment of challenging 
diseases such as sickle-cell anemia, cystic fibrosis, spinal muscular atrophy, and HIV 
infection. We envision that these collaborations which combine the powerful genome-
engineering tools and interesting research questions will result in potential solutions to 
various critical diseases, and serve as paradigms in gene therapy research. 
 Despite the effectiveness of the tools, a number of questions regarding to how the 
nucleases work still remain to be answered. These questions are discussed below. 
 Different DNA repair pathways lead to different outcomes of gene editing. Figure 
22 shows that NH- and NN-TALENs with similar levels of NHEJ-mediated mutation 
show different HR-mediated gene targeting. The discrepancy between levels of the two 
repair pathways may imply that NH- and NN-TALENs cleave DNAs differently. 
Interestingly, Figure 23 displays that the ratios of large-size deletion are different for NH- 
and NN-TALENs, which may further indicate different cleavage from these two types of 
TALENs. It will be useful to investigate what characteristics cause different ratios of HR 
and NHEJ, and how to shift pathway choices to favor NHEJ or HR in different uses of 
nucleases. 
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 Although some design guidelines of TALENs were deduced in Chapter 4, it is 
unclear how TALEN binding / DNA cleavage is affected by these design variables. 
Mechanistic study of TALEN-DNA binding in vitro is needed to further elucidate the 
importance of different design variables. Alternatively, molecular dynamics simulation of 
TALEN-DNA binding can also provide some insights and hypothesis that can be verified 
experimentally. In addition to current design variables considered in our scoring 
algorithm, there are likely more variables we need to take into account. The SAPTA 
scoring algorithm may be improved to better predict TALEN activity if these hidden 
variables are characterized in the future. A larger training data set and more sophisticated 
algorithm may also improve SAPTA. Machine learning and data mining approaches may 
be useful in analyzing the data set.    
 There is plenty of room for improving genome-engineering tool kit to make them 
more efficient, specific, and versatile, and using them to solve biological problems. 
Computational modeling and data analysis combined with experimental validation may 
be a viable approach for system improvement. Although numerous studies have been 
published following the development of TALENs and CRISPRs, the potential uses of the 
genome-engineering tools is yet to be fully explored. Collaboration between tool-
developing labs and labs with interesting biological questions will likely lead to 
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Table 6: Off-target analysis of KNH TALENs targeted to CXADR, CFTR, and AAVS1(PPP1R12C) using 
SMRT sequencing.  
The total number of mismatches in each binding site (T) as well as the number of mismatches in the left (L) 
and right (R) half-sites is provided as well as the closest annotated RefSeq gene, and the coordinates in the 
hg19 human genome build. The intended on-target gene is marked by “(on)” next to the gene name. Some 
sites failed to generate specific amplicons and are listed as "PCR Failure". One site did not obtain any 
sequencing reads passing quality metrics and is listed as "Seq Failure". 
 
 
Mismatches Mock NK NH NN 
Nuclease T L R Closest Gene hg19 Coordinates % indel % indel % indel % indel 
C3/C4 
0 0 0 CXADR (on) chr21:18965449 0 53.55% 65.24% 49.86% 
5 3 2 PRDX2 chr19:12909463 1.15%  0 1.40%  0 
5 2 3 CDKL4 chr2:39450719 2.55% 1.56% 2.16% 1.24% 
5 3 2 AEBP2 chr12:19699361 0 0 0 0 
7 2 5 NFIA chr1:61962413 0 0 0 0 
6 5 1 SP3 chr2:174563626 0 0 0 0 
6 4 2 ZNF91 chr19:23621161 
Seq 
Failure       
5 2 3 CDKL4 chr2:39450719 
PCR 
Failure       
5 3 2 CDKL4 chr2:39450721 
PCR 
Failure       
6 1 5 ABCA1 chr9:107696114 0 0 0 0 
8 5 3 CDH2 chr18:25842175 0 0 0 0 
6 2 4 GLCCI1 chr7:8088601 0 0 0 0 
6 3 3 DKFZp686O1327 chr2:145413307 0 0 0 0 
6 3 3 D21S2088E chr21:24359673 0 0 0 0 
6 3 3 TMEM215 chr9:32800075 0 0 0 0 
6 1 5 ABCA1 chr9:107696114 
PCR 
Failure       
7 4 3 SLCO1A2 chr12:21506376 0.21% 0.07% 0.43% 0.28% 
5 3 2 PRDX2 chr19:12909465 0  0  0  0 
5 2 3 NFAT5 chr16:69657715 
PCR 
Failure       
6 3 3 LGALS8 chr1:236675094 0 0 0 0.06% 
8 4 4 EFHA2 chr8:16930149 0 0 0 0 
7 3 4 RAP1A chr1:112167944 0 0 0 0 
7 2 5 TMEM2 chr9:74312571 0 0 0 0 
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Table 6 (continued). 
 
 
Mismatches Mock NK NH NN 
Nuclease T L R Closest Gene hg19 Coordinates % indel % indel % indel % indel 
F8/F9 
0 0 0 CFTR (on) chr7:117199507 0 49.62% 48.17% 52.44% 
11 5 6 GRM7 chr3:7743292 0 0 0 0 
11 5 6 SORCS1 chr10:109376387 0 0 0 0 
11 6 5 MIR4532 chr20:56564815 0 0 0 0 
11 6 5 SEMA3A chr7:83547837 0 0 0 0 
12 7 5 PHF20L1 chr8:133839511 0 0 0 0 
13 7 6 GHITM chr10:85331718 0 0 0 0 
12 5 7 OSBPL6 chr2:179132155 0 0 0 0 
12 7 5 IKZF2 chr2:213921336 0 0 0 0 
12 7 5 AKT3 chr1:243699384 0 0 0 0 
12 5 7 TSPEAR chr21:46083995 0 0 0 0 
12 5 7 ATP8B4 chr15:50345887 0.46% 0.24% 0.38% 0.36% 
12 5 7 FAM91A1 chr8:124770049 0 0 0 0 
12 5 7 ANKRD50 chr4:125700596 0 0 0 0 
12 5 7 MYB chr6:135443049 0 0 0 0 
12 7 5 SPANXN1 chrX:143753106 0.23% 0.15% 0.15% 0.15% 
12 6 6 RNU6-53 chr10:111205307 0 0 0 0 
12 6 6 RORB chr9:77272288 0 0 0 0 
12 6 6 PLA2G4C chr19:48598753 0 0 0 0 
14 7 7 SYT17 chr16:19171179 0 0 0 0 
12 6 6 FPR3 chr19:52322997 0 0 0 0 
14 7 7 PHYH chr10:13336769 0 0 0 0 
13 6 7 CDCA7L chr7:21977297 0.00% 0 0 0 
G1/G2 
0 0 0 PPP1R12C (on) chr19:55627036 0 48.53% 52.65% 58.31% 
8 6 2 PDLIM5 chr4:95416588 0 0 0 0 
8 4 4 CACNG4 chr17:65016227 0 0 0 0 
9 6 3 ARHGEF10L chr1:17913943 0 0 0 0 
9 3 6 CPSF7 chr11:61171976 0 0 0 0 
9 3 6 EDC4 chr16:67912248 0 0 0 0 
9 6 3 STOM chr9:124106256 0 0 0 0 
9 3 6 PLEKHG1 chr6:151106895 0 0 0 0 
9 6 3 MFSD6 chr2:191364289 0 0 0 0 
9 6 3 UMOD chr16:20349508 0 0 0 0 
9 3 6 POC1B chr12:89888350 0 0 0 0 




Table 6 (continued). 
 
Mismatches Mock NK NH NN 








9 6 3 CHD6 chr20:40459509 0 0 0 0 
9 3 6 RASSF6 chr4:74533040 0 0 0 0 
9 3 6 TMEM135 chr11:87351794 0 0 0 0 
9 5 4 SCARA5 chr8:27847586 
PCR 
Failure 
9 4 5 UBE2V2 chr8:49105234 
PCR 
Failure 
10 6 4 DPY19L1P1 chr7:32690655 
PCR 
Failure 
10 4 6 NUP35 chr2:184257506 0 0 0 0 
10 6 4 ZEB1 chr10:31889755 0 0 0 0 
10 6 4 HIVEP3 chr1:42546490 0 0.10% 0 0 
12 6 6 FLJ31662 chr1:96504572 0 0 0 0 
11 6 5 DDIT4L chr4:101002104 0 0 0 0 




Table 7: Potential off-target sites listed in the table above for KNH TALENs targeted to CXADR, CFTR, 
and AAVS1(PPP1R12C).  
TALEN half-sites are listed including the 5' base; mismatches relative to the intended binding site are given 
in lowercase. The right half-site is given as the 5'->3' sequence on the top DNA strand, so it is listed in the 
reverse anti-sense orientation to the sequence bound by the TALEN protein. 
 
Closest Gene Left Half-Site Spacer Right-Half Site 
CXADR (on) TCTCTTTTTTTCTTTTTGT agttcaagtacccttacaa GACTGATGGAATTACA 
PRDX2 cCTCTTTTTTTtTTTTTtT ttttttaaccaataccccatctctt AaAAAAAaAAAAAAAGAGA 
CDKL4 TCTCTTTTTTTtTTTTTtT gaagacttctgtcttcaaa AaAAAAAaAAAAAgAGAGA 
AEBP2 TtTCTTTTTTTtTTTTTGa agattgttttcttattagccttatta gCAAAAAGAAAAAAAaAGA 
NFIA TtTCTTTTTTTCTTaTTGT atcactttcagaatt gCtAgAAGAtAAAAAGAGg 
SP3 TCTCTcTgaTTCTTaTTGa aatagcttttgcttcca ACAAAAAaAAAAAAAGAGA 
ZNF91 TCTCTTTcTcTCcaTTTGT gacacccaggctggagtgtg ACAAAAAaAAAAAAAGAaA 
CDKL4 TCTCTTTTTTTtTTTTTtT gaagacttctgtcttcaaa AaAAAAAaAAAAAgAGAGA 
CDKL4 TCTtTTTTTTTtTTTTTGa agacttctgtcttca AaAAAAAaAAAAAAAGAGA 
ABCA1 TCTCTTTTTTTCTTTTTcT ttataaaatattttta ACAtAgAaAAAtAAAGAaA 
CDH2 TCTCaTTTTTaaTgTTTGa aaaaattctatttcttctagtcttcattt ACAAgtAGAAAAAAAGAGg 
GLCCI1 TtTCTTTTTTTgTTTTTGT ttttactattctggtttttataa ACAAAAAttgAAAAAGAtA 
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Table 7 (continued). 
 
Closest Gene Left Half-Site Spacer Right-Half Site 
DKFZp686O
1327 
TCTCaccTTTTCTTTTTGT aatctttttagaccagtaaagagaaa ACAAAAAcAAAAAcAGAaA 
D21S2088E TgTCTTTaTgTCTTTTTGT actgactatagt ACAAAAAGAtAtAAAGAaA 
TMEM215 TCTtTTTTTTaCTTTTTaT catgtttccatcaaacacttattcatt ACAAAAAGAAAAAtAGtaA 
ABCA1 TCTCTTTTTTTCTTTTTcT ttataaaatatttttaacat AgAAAAAtAAAgAAAaAtA 
SLCO1A2 cCTCTTTcTTTaTTTTTGg gatggtgctcagaaaaa AaAAAAAGAAAgAAAGAaA 
PRDX2 TCTtTTTTTTTtTTTTTtT ttttaaccaataccccatctctt AaAAAAAaAAAAAAAGAGA 
NFAT5 TCTtTTTTTTTCTTTTTtT tgcccaaacaaaaaggaaatttga AaAAAAAaAAAAAAAGAaA 
LGALS8 TCTCTcTTTTaCTTTTTtT aaagacttcttctcaaaa AtAAAAAGAAAgAAAGAaA 
EFHA2 cCcCTTTTTTTaTcTTTGT aaaaaagattatggc ttAAtAAGAAAAAAAtAGA 
RAP1A TCTtTTTTTTTtgTTTTGT ttttgtctttagaaaag ACAAAActAtAAAAAGAGg 







GRM7 TTTATTTCaAGtCaTCcCTTCa ggcctcagta AGAAtTGAAGgagGGtAATtAA 
SORCS1 TccATTTCCAaAaTTCcCTTCT gaattgccatgtcagcaaaatgg AGAAGTactGTtTGGAAAatAA 
MIR4532 TTTcTTTCCtttCcTCcCTTCT ttcttcttggactct gGAtGTGAtGTCTGGAgAcAAA 
SEMA3A aACCCTCTGcAGtaTCCAtTcCT ctgcaacacgtggtcaggatatt tGAAGaGcccTCTGGAAATAAA 
PHF20L1 TTTgaTTaCcGAaTaCcCTTCT gtgagtggtatgtcacaatacagaaatg AGAAGctcAGgCTGcAAATAAA 
GHITM aTcATTTaCAGAgcTCAgTaCT gccaaaagtacttagggggaaaagttggga AGAAtTGAttTCTGaAAgTtAA 
OSBPL6 TTaccTTCCccACTTCACTTCT cccatactcttaagctctattatagga tGAAaaGAAaaCTGaAAATAAc 
IKZF2 cTgAaTcCCAaACTTCttTTCT gatatgctattc AGAttTGAAGgCTGGAAgTcAA 
AKT3 TTTtcTTgCtGAtTTgAgTTCT ttataagattctgggtattagccctttttc AGAAGTaAAGTtTGcAAATAtt 
TSPEAR TTTATTaCCAtACTggACTTCc taaacagtgaagtaaa AagcaTGcAGcCTGGAAAgAAA 
ATP8B4 TaTATTTCCAGcaTTtACTaCT tggtggggggg tGggGTGAAGgtgGGgAATAAA 





MYB TTTAacTCCAGACTTCAacTtT ccactgagttttcgatatgtcacct AGAAGatAAcaCTGGAggaAAA 
SPANXN1 aTaAaTaCCAGAgTTCAaTTCa tacaaaagagcagcatttgtg tGAAGTGAAcTCTGGtAtTtAA 
RNU6-53 cTgATgcCCAGACTcCACTTgT agatattaaaattgccatttctggctt tGcAGTGAAGTCTGGAcATgcg 
RORB gcTcTTTCgAaACcTCACTTCT atcctcagtaaaggggagactggtcctaa AGAAGTaAAGgtTGtAAAgAtA 
PLA2G4C gTTcTgaCCAGtCTTCcCTTCT tgaatttgcttc cGAAGTGggtTaTGGAAAcAAA 
SYT17 caaATccCCAaACcTCACTTCT aaatctactgcatcacaatctct gGgtGaGgAGTCTGaAAATAAg 
FPR3 TcTcTTTaCAGAaaaCACTTCT cttaaagaaat AGggtTGAAGctTGGAAAgAAA 
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Table 7 (continued). 
 
Closest Gene Left Half-Site Spacer Right-Half Site 
PHYH TccATTcCCAGAaTTaAaTTaT tccctagtttagcatacc AGtAGgGAAGTCTttttATAAt 






PDLIM5 aCTGtCTAtCAGatGtTG accttaacaa CAtCTCCTGTTAGGtAGA 
CACNG4 gCTGCCTggCAGGAGcTG cggctgttgggaagcaatgccacccctt CACCTgCaGcTgGGCAGA 
ARHGEF10L TCTctCTtcCAGGAGaTc agctggttccaggagtcccagg CcCCTCCTcTgAGGCAGA 
CPSF7 cCTGgCaAACAGGAGGTG tgggattgggaggactgccaagcagtct tcaaTCCTGTggGGCAGA 
EDC4 TCTGCCTAcCtGcAGGTG tctgcacgagtgga aACCTCaTGaTgGGCgGc 
STOM TCTcCCTccCcGaAGGaG ggcgaatcagtgga ATttGGAGACTAGGtAGGAGGA 
PLEKHG1 TCTGCagAgCAGGAGGTG agagcaagtgaagctgagctc CACCTCCTGTcAGatcag 
MFSD6 TCTGCCTccaAGGAtaaG aaccccttatt tACCTCCTGTTAGaCAaA 
UMOD TCTGCCTggCAaGAGaaa agccctgaggttaagtggact CAaCTCCTGaaAGGCAGA 
POC1B TCTGCtTcAaAGGAGGTG gagtctgtttattt CtCCTCCctTTgGGCtGg 
BAI1 aCTGgCTAACAGGAGGgG atgcagcacatggtccat CACCggtTaaTAGGCAGg 
CHD6 TCTGtCTAAaAacAGGaa ctggaagtggcacatgccacttctgct CACaTCCTGTTgGcCAGA 
RASSF6 TCTaaCTAACAGcAGGTG agtggttttgaca CAaCTCCTGaTgGGtAtt 
TMEM135 TgaGCCTAgCAGGAGGTG ttgtgttgaacaag gACtTCgTGTTtGttAGA 
SCARA5 TCCaCCTTCCTccTCTtCTGgT cagctcctgggacggggctggaatg CACggCtTGTTAGcCAGA 
UBE2V2 TCTtCCTAgCAGGAGagG gaagataaggaggaagagg 
AggAGGAGgagAGGAAGGAGG
A 
DPY19L1P1 TCCTCCTTgCTAcTgcCCaaAT aagccagttatt CtCCTgCTtTaAGGCAGA 
NUP35 TCTGaaTAAgAGGAGGaG gaggaagaagaggaagatgaagaaa AgaAGGAGAagAaaAAGGAGGA 
ZEB1 TCtTCCTTCCcAcTCTgCTtcT gccttcatcctgcatcctct CACCTCCTGcTtctCAGA 
HIVEP3 TCTGaCTAcCAtataGTG tgggaactct 
ATCAtGAGAaaAGcAAGGAGG
A 
FLJ31662 TCccCCTAACAaGAaaTa agtgcaaacaaaaagtgaccactctaagac CAttTtgTGTTgaGCAGA 
DDIT4L cCaGCCTAAtAaGAaGTc aagtaaacacctcaatacaatccgatggat tAtgTaaTGTTAGGCAGA 






Table 8: Primers to PCR-amplify potential off-target sites in the table above for KNH TALENs targeted to 
CXADR, CFTR, and AAVS1(PPP1R12C).  
 
Closest Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
CXADR (on) CCCATAAGGAAGCAGTGTGATGAC GCTCTAATCTCTGTGCCTTGTGC 
PRDX2 AGGCCTCCCAAAATGCTGGGAT GCAGAAGATTGCTTAGGCCCAG 
CDKL4 CCCTGACTGTTGATAAGACTGGGT TGAGCAGAGATCATGCCACTGCAC 
AEBP2 GACATGCATGTTTGCTGGGCAGT GCAACCGATGGCAATCCTAAAGC 
NFIA CACGTTTTGTGCTATCCAGCCTTG ACTACTCCCTAGGAATGCTTGCC 
SP3 CAGGCTATAACTCTGGCAACAGTC CTGCACAATGTGCACATGTACCC 
ZNF91 GCTTACAGCCAACAGCTGTCTC CCCGGGACTACTCAGAACTTCTT 
CDKL4 CCCTGACTGTTGATAAGACTGGGT TGAGCAGAGATCATGCCACTGCAC 
CDKL4 CCCTGACTGTTGATAAGACTGGGT TGAGCAGAGATCATGCCACTGCAC 
ABCA1 ACTTCCTTAGAGAGAGAGAGGCC GGAAGGAAAGTGTGGTCAGTAGTG 
CDH2 GCTCTGAATCTTGGGGAAAGTGAC CCTGTCTCACTGACAATGCTAGGA 
GLCCI1 TTACCCTTTGTCCCAGAGGGAAC CTAATGAGAGGGCTTGCTGGTG 
DKFZp686O1327 GCTACAGTCTGCTAGAGGATGACA GCCAAGCAGACATTATGGAGGAC 
D21S2088E GGTCAGTACAGAGAAACGCACAG GGGGGTGGGTGTCTTCTATTTC 
TMEM215 CTTTCTGGCTTGCTCCTGTTTCTC GTAGAATGTCCCCCAGTCTGGAT 
ABCA1 ACTTCCTTAGAGAGAGAGAGGCC GGAAGGAAAGTGTGGTCAGTAGTG 
SLCO1A2 CCTCTCTGAGCAGTGCTACAAC CACAGCAATCTGCTATCTCCTACC 
PRDX2 GGCCTCCCAAAATGCTGGGAT GGCAGAAGATTGCTTAGGCCC 
NFAT5 CTCCCAAGGTGCTGGGATTAC GCCAACATGGTGAGACCCTG 
LGALS8 CGAGACTGAGCCACTGCCTT CCTGGCTCCTAAAGAACTCCAGA 
EFHA2 GGATGGGAGGATATGCATGCAAC CTGGCGGGTGTCAAATAGTATCG 
RAP1A GCTGTACCCACTTATTCTGGAGG CGTGGGTGATATAGCAAGACTCTG 
TMEM2 GCATTTCGAACCAAAGTCAGTCGG CCCCTGTGATACGTCAGTTTACC 
CFTR (on) CCCCTTCTCTGTGAACCTCTATC GGCATGCTTTGATGACGCTTCTG 
GRM7 TTAGCCAGGATGGTCTCGATCTC CCACTGTCATGGAGCTTAGTGTC 
SORCS1 TGAGCCCTTTGTGGTCTGGCA GGACAGGCATCACTTTGGTATGAG 
MIR4532 ACGTTCGCCTTCCCAGACCT TGGCTCCACAGTGCTACTGAAAC 
SEMA3A CCTTGATTTGCTCTCGGTCTCTTG CACCCAGCCTTCAGCTCACT 
PHF20L1 ACCCCCCCATCACCTCTTCA CCTGCACTGACAATGCAGGTCT 
GHITM GCTGAGCACTGCCTATGAGAAG CCTCTCTTTCCTCTCCACTACC 
OSBPL6 TTGCCACTGCACTCCAGCCT CTCTGCCCCTGATGAAACCTG 
IKZF2 CTGTGGTAGGATAGGCAGAGATCA GACTGCCTGTGACATCTGATGTTG 
AKT3 CCCATGTTTGTTGGCCATTTGCAC CCGGAGATTGACCTAGGCAAAG 
TSPEAR CCCAAGAATGCAAGGTTGGTTCAG GAGAGTCGACATATCCAGCAATCC 
ATP8B4 TCTCTTGGCCCCTAACAAAGCTC GAGGCAATCTCCCAAATGCTCC 
FAM91A1 CTGGTGTTCTATTGCACAGTAGGG CAGTGTCAGCTCCTATCGTTTGC 
ANKRD50 AGTGGTAGACTGTCCTGCAGGT CAGTTTCCACAGGTCAGAAGCC 
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Table 8 (continued). 
 
Closest Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
MYB GGGGCATCAGTCTTGTAGGG TGGAAGACCTGTGTCCCCAAC 
SPANXN1 CTGCACCTGGCTAACTTGGATTC CTCGGAGGTGAAGGCAACAG 
RNU6-53 CAGTGATCCTAGGTTACTCCGTG TTGGCTTTCCAGGGAGAATGGTAG 
RORB TCGATCTCCTGACCTCGTGATCT GGATGAGCACAGTTTGTCACATGG 
PLA2G4C GGCAAACTAGACCCTCAGAAGGA CTGGTTCTGTGCTGGGACTC 
SYT17 GTAGGAAGTGTGTGCACATCACC GGTAACAGAGTGAGACCCTGTCAA 
FPR3 GCATTAGCTGGAGTGCTAAGGAC CCACTGTCTCTCGTCTTCCC 
PHYH GCAGACTTGAGGGGTGGTTTC CCATGCCTCTGTTTCCTCATCTG 
CDCA7L GAGATTGCACCACTGCACCC GGCTTAAGGTAAGGGTCCAACCTA 
PPP1R12C 
(on) CAGGATCCTCTCTGGCTCCAT CCTTATATTCCCAGGGCCGG 
PDLIM5 GACCAAATCAGGTTTCCCGTCAG TGACCACAGAGCATACCATGCC 
CACNG4 AACCCACAAGGGCTGGAGAG TCCTCACTCCATCCTGCCCT 
ARHGEF10L ACCTGAGGTGCTCACCCAGT AGTGGATCAGTGGGGGGTCT 
CPSF7 CCCGGAGAATCAGAAACTCATACG CATCTCCTCACCTTGATCAGGAC 
EDC4 GCAGATCTACATTGAGGGGCAAG CAAGGCAGTGAGTGACTGGC 
STOM AGAGAAGGCAGTGAAAGCTGCTAG GCAGGACATGATGTGTGGCTTTG 
PLEKHG1 CCCTTCCCAGCATATCTCTCC GGGATGGTTTTGGGATGACTCAAG 
MFSD6 CTGCTGGTGATGTTCTACTCATGG TTTACTGAGCCCCCCAAGCC 
UMOD ATTTCGGAGGGAGGCTGAACAC AAAGAGGAGACAAGTCGGGGAG 
POC1B CTCCGCTTCACAAAAGGTGAAGTC GGGTTCCAGGAGAATCAAAGCAG 
BAI1 TCCATCACCGGTTAACAGGAGG GCCAGTGATGGACCATGTGC 
CHD6 GCTGTGTCTGTGTTTGCTTCTCC GACTCTTAGTTGGACACTTGGCC 
RASSF6 CCTCCCTAGCACTTACCAAGAGA CCCATTGTTACCCCAGAACATCC 
TMEM135 GGCACCTGTCAAGATGTACGG CTTCCCAGGCACAAAGTTTCCTC 
SCARA5 CAAAGGCAATAGCCTCTGCTTCC TGTGCACTCACATCTGGCCC 
UBE2V2 GGTAGAAGCTGCCTCCAAACCA CTTCTTCTCCTCCTCTCCTCC 
DPY19L1P1 CTCTAGTGGCATTCCATCCACTC TTTGGCCTGCTGTACTCCAGGT 
NUP35 GACTGAGTGAGACTCTGCCTCAA CTCTGTCTCTCTCTCTCTTTCTCC 
ZEB1 CTTTCTCATTCCCTCCAGCCAC CAGTGCTGGCATTTCAGGCACTGT 
HIVEP3 GGCTGAGGAGGCCTTAGGAA TGGTTTGGCTCTCTGTCACCATC 
FLJ31662 CTGTCACTCAGAACAAGCCATGG GTTTCTGAAGAACAGGGAGGCC 
DDIT4L GGGTGCAGCCTAGGTTATAGTC TAAATGTCACTTCCTCCCAAGGCC 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6: Primers used for T7E1 assay and SMRT sequencing analysis.  
 








HBB B-glo-Fwd B-glo-Rev 404 
CXADR CAR-F5 CAR-R4 427 
CFTR CFTR-F CFTR-R2 501 
AAVS1 AAV-F AAV-R 528 
CCR5 CCR5_1_10_1_F CCR5_1_10_1_R 477 
ATF4 ATF4-F ATF4-R 494 
HBD delta-6F delta-6R 504 
        








CCR5 CCR5_1_10_1_F CCR5_1_10_1_R 477 
  CCR5_1_10_2_F CCR5_1_10_2_R 477 
        
CCR2 CCR2_1_10_1_F CCR2_1_10_1_R 381 
  CCR2_1_10_2_F CCR2_1_10_2_R 381 
        
ATF4 ATF4F_1 ATF4R_1 494 
  ATF4F_2 ATF4R_2 494 
        
USP28 USP28F_1 USP28R_1 342 
  USP28F_2 USP28R_2 342 
        
RNF157 RNF157F_1 RNF157R_1 463 
  RNF157F_2 RNF157R_2 463 
        
CTAG1B CTAG1BF_1 CTAG1BR_1 347 
  CTAG1BF_2 CTAG1BR_2 347 
 
aEach locus may use barcode-containing primers if PCRs of the same locus from different samples were 
pooled. Barcodes are underlined in the sequences below.
 186
Table 6 (continued). 
 













CCR5_1_10_1_F CTGTGTGCAG GCACAGGGTGGAACAAGATGG 
CCR5_1_10_1_R ACTACATATG ACCACCCCAAAGGTGACCGT 
CCR5_1_10_2_F AGTCGACACT GCACAGGGTGGAACAAGATGG 
CCR5_1_10_2_R GCATAGATCG ACCACCCCAAAGGTGACCGT 
CCR2_1_10_1_F CACGATACTC TTGAACAAGGACGCATTTCCCCAG 
CCR2_1_10_1_R ATCGCAGAGA CAAAGACCCACTCATTTGCAGCAG 
CCR2_1_10_2_F AGAGTCTACA TTGAACAAGGACGCATTTCCCCAG 
CCR2_1_10_2_R TATCTCATAC CAAAGACCCACTCATTTGCAGCAG 
ATF4F_1 GGTAGCATAGATCGC AGAAGTCCCGCCTCATAAGTGGAAG 
ATF4R_1 CCATCCTACATATGA CATTTGAGTGATGGGGCCAAGTGAG 
ATF4F_2 GGTAGTCGTATACGC AGAAGTCCCGCCTCATAAGTGGAAG 
ATF4R_2 CCATCGTCGACACTA CATTTGAGTGATGGGGCCAAGTGAG 
USP28F_1 GGTAGCTACATATGA CTTAAGCCATGGCGCTTCTCAGG 
USP28R_1 CCATCTGTGTGCAGC GAAGGCATCCTCCTTGCTGTTATTGG 
USP28F_2 GGTAGCTCGACTGCA CTTAAGCCATGGCGCTTCTCAGG 
USP28R_2 CCATCGTCGACACTA GAAGGCATCCTCCTTGCTGTTATTGG 
RNF157F_1 GGTAGCATAGATCGC AAGTGTCATCCAACGTGGTCAAAAGG
RNF157R_1 CCATCCTACATATGA CTTAAGCCATGGCGCTTCCCAC 
RNF157F_2 GGTAGTCGTATACGC AAGTGTCATCCAACGTGGTCAAAAGG
RNF157R_2 CCATCCTCGACTGCA CTTAAGCCATGGCGCTTCCCAC 
CTAG1BF_1 GGTAGCTACATATGA GCTTAAGCCGTAGCACTTCTCACAG 
CTAG1BR_1 CCATCCTACATATGA CCAAAGAAAGCATCCTCCTTGCCATC 
CTAG1BF_2 GGTAGGTCGACACTA GCTTAAGCCGTAGCACTTCTCACAG 
CTAG1BR_2 CCATCGTCGACACTA CCAAAGAAAGCATCCTCCTTGCCATC 
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Table 7: Target sequences of CRISPRs (Chapter 5).  
Target genes, target site sequences, and PAM sequences are listed. 
 
 
Gene Storage Index Protospacer Target (5' to 3') PAM 
HBB R-01 GTGAACGTGGATGAAGTTGG  TGG 
HBB R-03 GACGTTCACCTTGCCCCACA  GGG 
HBB R-04 GCACGTTCACCTTGCCCCAC  AGG 
HBB R-05 GGTCTGCCGTTACTGCCCTG  TGG 
HBB R-06 GGTTACTGCCCTGTGGGGCA  AGG 
HBB R-07 GAGGTGAACGTGGATGAAGT  TGG 
HBB R-08 GCTGTGGGGCAAGGTGAACG  TGG 
EGFP R-19 GGTGGTGCAGATGAACTTCA  GGG 
EGFP R-20 GACCAGGATGGGCACCACCC  CGG 
CCR5 R-25 GTGTTCATCTTTGGTTTTGT  GGG 
CCR5 R-26 GCTGCCGCCCAGTGGGACTT  TGG 
CCR5 R-27 GGCAGCATAGTGAGCCCAGA  AGG 
CCR5 R-29 GTGAGTAGAGCGGAGGCAGG  AGG 
CCR5 R-30 GTAGAGCGGAGGCAGGAGGC  GGG 
ERCC5 R-31 GCCAAGCACTTAAAGGAGTC  CGG 
ERCC5 R-33 GCAAGCACTTAAAGGAGTCC  GGG 
ERCC5 R-35 GTGAGTTCCCATGGCGATCC  CGG 
ERCC5 R-36 GCTATTGAAGAAACAGACTT  TGG 
ERCC5 R-38 GATTTTCTATTGAGTTCCCA  TGG 
ERCC5 R-39 GGAAACAAAGTGAGAAGATG  AGG 
ERCC5 R-40 GCCTATTTTTGTGTTTGATG  GGG 
TARDBP R-41 GCAGAGCAGTTGGGGTATGA  TGG 
TARDBP R-42 GGCAGCACTACAGAGCAGTT  GGG 
TARDBP R-43 GCAGCACTACAGAGCAGTTG  GGG 
TARDBP R-44 GCCTGACTGGTTCTGCTGGC  TGG 
HPRT1 R-52 GTTTGTGTCATTAGTGAAAC  TGG 
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